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ABSTRACT

The opportunistic fungus Candida albicans is a commensal member of the human
microflora and is the most common causative agent of fungal-related disease with
particular significance in immunocompromised individuals. Emerging drug resistance is a
major problem in Candida, contributed by enzymes involved in the detoxification of
xenobiotics and pharmacological agents. One such enzyme, cytochrome b5 reductase
(cb5r), has a high pharmacological significance owing to its role in fatty acid elongation,
ergosterol (or cholesterol in mammals) biosynthesis, and cytochrome P450-mediated
detoxification of xenobiotics.

We have compared the kinetic, biochemical, and pharmacological characteristics
of C. albicans cb5r isoforms, Cbr1 and Mcr1, as compared to the mammalian control, rat
cb5r. We have observed two key structural differences between the fungal and
mammalian proteins that may account for decreased thermal stability and inhibitor
specificity of C. albicans Cbr1. Substrate binding affinity and catalytic efficiencies, as
well as investigation in the flavin-binding environment, were comparable between the
fungal and rat enzymes. In S. cerevisiae, CBR1 and MCR1 knockout strains have been
challenged with environmental stressors and subsequently shown to have a role in azole
and amphotericin B resistance. Our results of potential protein interactions of C. albicans
Cbr1 describe proteins involved in the weak acid stress response, implying a novel role of

ix

the protein in pathogenicity. Conclusively, this report describes potential inhibitors of the
fungal protein, as well as elaborating upon its important role in ergosterol biosynthesis
and

possible

mechanisms

of

CYP450-mediated

x

drug

detoxification.

1. INTRODUCTION

CANDIDA ALBICANS AND HUMAN DISEASE

Candida albicans is a commensal member of the human microflora that is found
on the mucosal surfaces of the oral, gastrointestinal, and urogenital tract, most of the time
without causing any apparent symptoms [1, 2]. However, C. albicans is also an
opportunistic pathogen that is the most common causative agent of fungal-associated
disease, including fungal myocarditis, and Candida species are the fourth most common
causative agents of nosocomial infections [3].

C. albicans infections have a wide

presentation of symptoms, ranging from a mild mucocutaneous oral thrush to a more
severe and disseminated candidiasis. In many patients, especially immunocompromised
patients, the disease can be debilitating and is often recurrent [4].
The life cycle and morphology of C. albicans is complex, and in many cases the
morphogenetic properties are in response to the surrounding environment of the organism
[5, 6]. The organism is classified as a dimorphic fungus, having both a yeast and hyphal
life stage.

However, some recent publications opt for the “polymorphic” or

“pleomorphic” classification to describe the many cellular forms in addition to the yeast
and hyphae morphologies [7], including thick-walled chlamydospores in response to
harsh environment conditions, an intermediate pseudohyphal form, or a combination of
the cell morphologies, such as the case in biofilm formations [8]. The dimorphic life
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cycle includes the single spherical yeast cells which multiply by budding, and the
filamentous hyphal form that is associated with pathogenicity in C. albicans. This
phenotypic yeast-to-hyphal transformation is critical in host tissue adhesion and invasion,
and clinical isolates lacking the phenotypic switching ability were less severe in disease
manifestations. Host tissue adhesion occurs by the yeast cells binding to the fibronectin
of host epithelial cells, followed by extracellular proteinase activity to facilitate tissue
invasion. Once inside the host cell, the yeast-to-hyphal transformation has occurred, and
C. albicans infection can continue within the host (Figure 1) [2]. The host-pathogen
interactions that occur after host cell invasion depend largely on the location of infection
in the host and the morphological state of the fungus.

Figure 1. Pathogenicity of Candida albicans Attachment and Invasion.
C. albicans has the ability to adhere to host epithelial cells via mannoprotein
components of the fungus that can bind to extracellular matrix (ECM)
proteins. Transformation from the yeast to the hyphal form is associated
with increased pathogenicity and virulence (Adapted from Rupp, 2004).

Although virulence mechanisms in C. albicans are important factors in disease
manifestation, the host immune state is also a key determining factor [1]. In most
persons, the fungus exists in a commensal state with the host, and there is a healthy
balance between the microbiotic flora. However, certain factors can predispose an
2

individual to fungal infections, including: hospitalization (nosocomial infection,
specifically ICUs), extremes of age (e.g. premature infants, elderly), immunosuppression
due to chemotheraphy or organ transplantation, disruption of normal bacterial flora
during antibiotic therapy, metabolic dysfunction, and an immunocompromised system
lacking cell-mediated immunity such as in patients with HIV disease [9]. Mild clinical
infections usually involve mucosal and/or mucocutaneous infections, commonly thrush,
and are treated with antifungal agents that restore the normal flora balance and combat
infection. However, serious disease manifestations occur when the fungus enters the
bloodstream resulting in candidosis, as well as in cases of antifungal resistant isolates that
do not respond to the current therapeutic options. The incidence of invasive fungal
infections has risen dramatically in the past few decades, and this increase can be
attributed in part to emerging fungal drug resistance to existing treatment options [4, 10].

ANTIFUNGAL THERAPEUTICS
Classes of Antifungal Agents
Fungal infections have emerged in the past few decades as a significant threat,
and this is complicated by a limited number of treatment options, due to clinical efficacy,
toxicity, and development of resistance against the current treatment options [10, 11].
Currently, there are four main classes of antifungal agents, based on their mechanism of
action: the polyenes, azoles, allylamines, and echinocandins [12]. The most widely used
antifungal agents are the azoles, specifically fluconazole (FLZ), and the polyene
amphotericin B (AmB) (Figure 2).
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Figure 2. Current Antifungal Drug Targets.
The five main classes of antifungals are the polyenes (direct membrane damage), the
azoles and allyamines (inhibitors of ergosterol biosynthesis), the echinocandins
(inhibitors of glucan synthesis in the cell wall), and those classified as other mechanism
(such as grisofulvin inhibiting microtubule assembly, or 5-flucytosine targeting nucleic
acid synthesis) (Adapted from Tourno, 2005).

The cell membrane of fungi is an attractive drug target since the major sterol
component of the cell membrane is ergosterol, in contrast to the cholesterol in
mammalian cell membranes. Most of the enzymes in the ergosterol biosynthesis pathway
belong to the cytochrome P450 (CYP) family of proteins, including Erg11 and Erg1, the
target of the azoles and allylamines, respectively [13]. In the ergosterol biosynthesis
pathway that converts acetic acid to ergosterol for use as the predominant sterol in the
fungal cell membrane, genes upstream of Erg11 are essential in S. cerevisiae, comprised
of other members of the CYP family preceding the formation of the lanosterol
intermediate (Figure 3) [14]. The azoles inhibit the action of Erg11p (lanosterol 14αdemethylase) in the conversion of lanosterol [14, 15]. However, it is not the lack of
4

ergosterol in the cell membrane that leads to fungal cell death, but rather the buildup of
14-methylated toxic intermediates (specifically 14-methylergosta-3,6-diol). In the case of
Erg11p inhibition, alternative pathways of sterol biosynthesis from the lanosterol
intermediate can be utilized, and this accounts for differences in sterol composition in
fungal cell membranes that have mutations in CYP genes crucial in this pathway [16].

Figure 3. Inhibitors of the Ergosterol Biosynthesis Pathway.
Allylamines target the Erg1 enzyme, squalene epoxidase, whereas the azole family
targets the downstream enzyme Erg11, C-14 lanosterol demethylase. It is not the
inhibition of the Erg11 enzyme, but rather the accumulation of the 14-methylated
intermediates that are responsible for cell death.

Azoles were first synthesized in the 1960s, and have been widely used against C.
albicans and other dimorphic fungi [17]. The two clinically relevant groups of azoles are
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the triazoles (e.g. fluconazole, itraconazole) and the imidazoles (e.g. ketoconazole),
which were first introduced in the 1980s and remain in use today [18].
In addition to the azoles, AmB also plays a significant role in the treatment of
fungal infections, and is classified in the group of polyene macrolides that interact with
membrane sterols as their antifungal mode of action [17]. These large compounds are
produced by Streptomyces species, comprised of lactone rings containing varying
numbers of conjugated double bonds (hence the polyene nomenclature) and usually a
single sugar moiety. AmB is a heptaene that has a higher affinity for ergosterol, rather
than membrane cholesterol, and is the most widely used polyene antifungal [14].
Although its specific mode of action is not completely understood, AmB is thought to
bind tightly to ergosterol, generating pores in the membrane and thereby causing leakage
of intracellular ions and/or other cellular components that subsequently lead to cell death
[15, 19].

Emerging Drug Resistance and Challenges in Treatment
The incidence of fungal infections continues to rise, and this is further
complicated by an already limited availability of antifungal therapeutic options, as well
as an increasing emergence of drug resistance against the current drug treatments.
Antifungal drug resistance can be attributed to many causes, including the widespread
use of the current therapeutics as well as repeated treatment of immunocompromised
individuals with recurrent infections [4, 14]. The other side of the spectrum is the ability
of the fungi to develop its own resistance mechanisms, and it crucial to understand these
mechanisms for the long-term benefit of development of new antifungal therapeutics.
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Although the azoles have been well established in their mechanism of action,
emerging drug resistance against this antifungal class has been frequently observed [17,
20].

ATP-binding cassette (ABC) multidrug transporters in C. albicans have been

implicated in azole sensitivity and resistance, as well as being involved in multidrug
cross-resistance between other classes of antifungal drugs. Multidrug resistance (MDR)
transporters work in collaboration with the ABC transporters, causing cross-resistance to
other classes of antifungals as well [20-22]. It is crucial to explore the mechanisms of
resistance, as well as the fungal response to the current treatments, as it may assist in the
development of next-generation antifungals, understanding of combination therapies,
and/or the identification of novel drug targets.

CYTOCHROME B5 REDUCTASE
Overview
Cytochrome b5 reductase (cb5r, EC 1.6.2.2) catalyzes the transfer of two reducing
equivalents from nicotinamide adenine dinucleotide (NADH), the physiological electron
donor, to two molecules of cytochrome b5 (cb5), its standard electron acceptor [23, 24] in
the reaction sequence shown below:
NADH + 2 ferricytochrome b5  NAD+ + 2 ferrocytochrome b5
The enzyme contains a single flavin adenine dinucleotide (FAD) prosthetic group and is a
member of the FNR superfamily of flavoprotein oxidoreductases, named after its
prototypical member, ferredoxin:NADP+ reductase (FNR) [25]. In the FNR family, there
are four conserved motifs: two NADH binding motifs, a flavin-binding motif, and a
FMN/FAD selectivity motif [26, 27].

Cb5r is amphipathic, comprised of a short
7

hydrophobic N-terminal membrane-anchoring alpha helix, and a larger hydrophilic
catalytic domain containing the NADH- and FAD-binding motifs. The NADH and FAD
binding domains are hinged by a short segment composed of β-sheets that serves to orient
these domains around the enzyme’s active site containing FAD [28-30]. The majority of
the interactions with the FAD prosthetic group occur with the adenine dinucleotide
moiety of the flavin, and this FAD-binding lobe also creates a “lid” covering this
prosthetic group. The rate-limiting step of the reaction has been identified as the direct
hydride transfer from the reduced pyridine nucleotide to the FAD prosthetic group [31].

Figure 4. Crystal Structure of Soluble Human Cb5r in Complex with FAD
(PDB ID: 1UMK).
The protein has an amino-terminal FAD-binding lobe and a carboxyl-terminal NADHbinding lobe. It is amphipathic, having a small hydrophobic N-terminal membraneanchoring domain, as well as a larger hydrophilic domain that contains the catalytic
portions of the protein. This enzyme is located membrane-bound in the outer
mitochondrial membrane and ER. Humans also have an additional isoform located in
erythrocytes that only contains the soluble hydrophilic fraction. This is the form shown
above, that lacks the N-terminal transmembrane domain sequence.
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In mammals, the soluble form of cb5r lacking the N-terminal membrane-anchoring
domain is found in erythrocytes, whereas membrane-bound cb5r is found in the
endoplasmic reticulum (ER) and outer mitochondrial membrane (OMM).

This

membrane-bound form participates in a vast array of biological processes, including fatty
acid desaturation and elongation, ergosterol biosynthesis (cholesterol biosynthesis in
mammals), and cytochrome P450-mediated detoxification of xenobiotics [29, 32-34]

Figure 5. Electron flow between cb5r and cytochrome P450 proteins, utilizing both
NADH and NADPH as electron donors.

The CYP family is a large ubiquitous group of enzymes that constitute the
majority of enzymes involved in xenobiotic metabolism as well as sterol biosynthesis. In
contrast to NADH as the source of electrons for cb5r, nicotinamide adenine dinucleotide
phosphate (NADPH) is the electron donor necessary for CYP reduction. However, cb5,
the physiologic electron acceptor of cb5r, can also be reduced by members of the CYP
family [35, 36]. In human CYP 2B4, catalysis is 10- to 100-fold faster in the presence of
cb5, and other human CYP drug metabolizing enzymes are stimulated by the presence of
cb5 as well; however, in other CYP enzymes cb5 had an inhibitory effect, and sometimes
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had no effect at all [37]. The involvement of cb5r and cb5 in CYP systems is still
uncertain and incomplete, and even appear to change depending on the surrounding
environmental conditions [38, 39]

Methemoglobinemia
In humans, mutations in the cb5r gene and deficiency in cb5r protein are
associated with recessive congenital methemoglobinemia (RCM), a hereditary disease
with

severe

and

potentially

fatal

physiological

complications

[32,

40].

Methemoglobinemia occurs when there are increased levels of methemoglobin in the
bloodstream.

To maintain lowered levels of methemoglobin, cb5r functions in the

reduction of methemoglobin, returning hemoglobin to its functional ferrous form that can
bind oxygen. Although methemoglobinemia is a heritable disease, it can also be acquired
after exposure to certain substances that cause an increased rate of methemoglobin
production, such as some nitrates and anesthetics [41-43].

Fungal cb5r
C. albicans and other fungi such as Saccharomyces cerevisiae have two
membrane-bound isoforms of cb5r: Cbr1 located in the ER, and Mcr1 located in the
OMM. In S. cerevisiae the ER-located Cbr1 is the more abundant isoform, and largethorough put protein expression analysis in yeast suggest twice as many Cbr1 molecules
per cell as compared to the mitochondrial Mcr1 isoform [44].
The majority of the previous studies on cb5r have been performed in mammalian
organisms, such as rat, dog, and pig [25, 26, 33, 45, 46].
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Fungal cb5r has been

investigated in certain non-pathogenic fungi, such as the slime mold Physarum and the
dimorphic fungus Mortierella, although thorough analysis has not been performed in a
fungal pathogen such as C. albicans [43, 47]. The MCR1 isoform, as well as the CYB5
electron acceptor in certain analyses, has been identified in genome-wide microarray
analysis of the fungal response to certain therapeutics (ketoconazole, flucytosine), as well
as other environmental stresses (oxidative stress, biofilm formation).

Due to its

involvement in biological processes, as well as the response to pharmaceutical or
chemical compounds, C. albicans cb5r should be examined in its potential as a novel
antifungal drug target and/or other significant roles in multidrug resistance mechanisms.
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RESEARCH AIMS AND APPROACHES

The opportunistic fungus Candida albicans is a commensal member of the human
microflora and is the most common causative agent of fungal-related disease with
particular significance in immunocompromised individuals with HIV disease/AIDS,
ranging from mild clinical manifestations such as oral thrush to serious disseminated and
potentially fatal candidiasis. Emerging drug resistance is a major problem in Candida,
contributed by enzymes

involved in

the

detoxification of xenobiotics and

pharmacological agents. One such enzyme, cytochrome b5 reductase (cb5r), has a high
pharmacological significance owing to its role in fatty acid elongation, ergosterol (or
cholesterol in mammals) biosynthesis, and cytochrome P450-mediated detoxification of
xenobiotics. The objective of this project is to characterize C. albicans cb5r and its
electron acceptor, cytochrome b5 (cb5), as potential novel drug targets.
In order to accomplish this objective, the genes for the cb5r isoforms, CBR1 and
MCR1, as well as its electron acceptor, cb5, have been cloned from C. albicans and we
have optimized recombinant protein expression in E. coli as His6-tagged fusion proteins.
Biochemical, kinetic, and pharmacological characterization in order to elucidate the
properties of the C. albicans cb5r versus its mammalian counterpart has been performed.
We have also utilized pull-down assays to identify the protein-protein interactions of the
Cbr1 and cb5, with other cytoplasmic and/or membrane-bound proteins, which may help
in establishing therapeutic targets for subsequent drug discovery. Phylogenetic analysis
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revealed that both cb5r and cb5 from C. albicans have highest homology to their plant
counterparts, but lower homology to human cb5r and cb5. Interestingly, plant cb5r has
been identified as an herbicidal target, making these plant inhibitors promising candidates
as a new class of antifungals against Candida cb5r. Identification of novel drug targets
has particular significance to combat multiple drug resistance in this opportunistic
microbial pathogen.

AIM 1: Kinetic, Biochemical, and Pharmacological Characterization of C. albicans
cb5r.
While cb5r has been well characterized in mammals such as rat and dog, nothing is
known about the enzymatic properties of cb5r in a pathogenic fungus such as C. albicans.
Recombinant C. albicans cb5r has been cloned, expressed, and purified in order to
characterize the kinetic, biochemical, and pharmaceutical properties of the fungal protein
in comparison to rat cb5r. In this specific aim I have tested the hypothesis that C.
albicans cb5r differs from mammalian cb5r in its kinetic, biochemical, and
pharmacological characteristics. The following techniques were utilized:
a. Spectrophotometric analysis by UV/Visible absorption spectra
b. Initial-rate enzyme kinetics (determination of Km, Vmax, kcat values)
c. Circular dichroism spectroscopy
d. Thermal stability profiling to identify T50 and activation energy (Arrhenius plot
analysis)
e. Pharmacological characterization using potential cb5r inhibitors
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AIM 2: Assess the Knockout Phenotype of the Two cb5r Isoforms, CBR1 and
MCR1, on Cell Growth and Viability in Candida albicans and the Yeast Model
System Saccharomyces cerevisiae.
In this specific aim, I have observed the effects of cb5r knockouts in the yeast model
system, S. cerevisiae. S. cerevisiae is a prime model for gene knockout studies since it is
a haploid organism, and it is closely related to the diploid C. albicans. C. albicans and S.
cerevisiae have two isoforms of cb5r (ER-specific Cbr1 and mitochondrial outer
membrane-specific Mcr1), and therefore knockouts of each isoform will be obtained to
investigate their individual phenotype. Thus, Cbr1 and Mcr1 knockouts have been
compared to wild-type yeast to investigate their susceptibility to potential environmental
stresses such as temperature and heat shock, pH, oxidative stress, and nutrient
availability, as well as challenge to selected antifungal therapeutics. Hence, in this
specific aim I have tested the hypothesis that S. cerevisiae cb5r knockouts are affected
by environmental stresses and antifungal compounds. The following assays were
utilized to investigate this hypothesis:
a. Growth rate and viability:
i.

at various temperatures and heat shock (25ºC, 30ºC, 37ºC)

ii.

at various pH values (pH 5.5, pH 7.4, pH 10)

iii.

in response to oxidative stress (0.5 and 2.0 mM H2O2)

iv.

during reduced nutrient availability or starvation

b. Saccharomyces double knockout studies:
i.

Inhibition in the presence of selected antifungal compounds

ii.

Sterol analysis of the cell wall
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AIM 3: Identify Cellular Proteins that Interact with C. albicans cb5r Through
Protein Pull-Down Assays and Proteomic Analysis.
Cb5r is involved in numerous biological processes where cb5 acts as the standard
physiological electron acceptor. However, there is evidence that cb5r may interact with
proteins other than cb5, such as members of the cytochrome P450 family involved in drug
detoxification. In order to elucidate potential interactions of cb5r with other cytoplasmic
proteins, protein pull-down assays or co-immunoprecipitation will be discussed. This
information will provide valuable insight into the identification of novel drug targets
related to cb5r and drug resistance. In this specific aim I have tested the hypothesis that
C. albicans cb5r interacts with other cellular proteins in addition to cb5. This
hypothesis was examined in the following experiments:
a. His6–tagged protein pull-down assay to identify cellular proteins that interact
with C. albicans cb5r
b. Co-Immunoprecipitation using anti-cb5r antibodies to identify cellular proteins
that interact with C. albicans cb5r
c. Identification

of

co-precipitated

interacting

spectrometry (MALDI-TOF/TOF)
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proteins

by

tandem

mass

2. MATERIALS AND METHODS

MATERIALS
Molecular Biology Reagents
Oligonucleotide primers were obtained from Integrated DNA Technologies (Coralville,
IA). Restriction enzymes were purchased from Promega (Madison, WI). Epicurian
Escherichia coli BL21 (DE3) RIPL cells were obtained from Stratagene (La Jolla, CA)
and the pET-23b expression vector was purchased from Novagen (Madison, WI). Kits for
agarose gel extraction and plasmid preparation, as well as isopropyl-β-Dthioglucopyranoside (IPTG) and Ni-NTA agarose, were purchased from Qiagen, Inc.
(Valencia, CA).

Superdex™ 75 gel filtration media used in size exclusion

chromatography (SEC) was purchased from GE Healthcare (formerly Amersham
Biosciences, Piscataway, NJ).

HPLC-grade ergosterol was purchased from Sigma

Chemical Co. (St. Louis, MO). The Molecular Biology Core Facility at the H. Lee
Moffitt Cancer Center and Research Institute (Tampa, Florida) performed nucleotide
sequencing for all samples.

Enzymology and Spectroscopy Reagents
MOPS, riboflavin, phenylmethylsulfonyl fluoride (PMSF), NADH and the substrate and
nucleotide analogues used in the enzyme inhibition studies were obtained from Sigma
Chemical Co. (St. Louis, MO).
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Saccharomyces cerevisiae Knockout Strains
S. cerevisiae strains were obtained through the Saccharomyces Genome Deletion Project
(Stanford) and purchased from Open Biosystems: BY4742 wild-type strain (MAT α,
leu2, ura3, his3, lys2), cbr1Δ (MAT a, isogenic wild-type strain BY4741; leu2, ura3,
his3, met15), and mcr1Δ (MAT α, isogenic wild-type strain BY4742) [48].

METHODS

Cloning of C. albicans CBR1 and MCR1 cytochrome b5 reductase isoforms and
cytochrome b5
Genomic DNA was extracted from the wild-type Candida albicans strain
SC5314. Primers were designed to clone full-length, as well as truncated C. albicans
versions that lack the transmembrane domain (∆Threonine-45 CBR1 and ∆Threonine-46
MCR1). Each oligonucleotide sequence encoded a His6-tag preceded by a Met, as well as
restriction endonuclease sites used for subcloning into the pET-23b protein expression
vector system for subsequent protein purification (Primers shown in Table 1). PCR was
then used to amplify the C. albicans CBR1 gene (Candida Genome Database systematic
name: orf19.1801; Saccharomyces Genome Database ID: YIL043C) and MCR1 gene
(CGD systematic name: orf19.3507; SGD ID: YKL150W) from the gDNA. This construct
was then subcloned into the pET-23b protein expression vector using EcoRI and XhoI
restriction sites and transformed into E. coli XL-10 Gold. The construct was confirmed
by sequencing, and subsequently transformed into E. coli BL21 (DE-3) RIPL cells that
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contain additional tRNAs of rare Arg, Ile, Pro, and Leu codons to optimize recombinant
expression of eukaryotic proteins in the E. coli BL21 (DE-3) strain.
Due to the small size of the C. albicans ∆G101-His6-cb5 protein (11.2 kDa),
purification using the pET-23b vector followed by Ni-NTA did not succeed in a
significant yield of purified product. Therefore, this protein was successfully expressed
using the IMPACT-TWIN vector, pTWIN1 (NEB). In this method, the target protein
expression sequence is adjacent to an intein endoprotease-coding domain (thiol inducible)
linked to a chitin binding-domain (CBD) that allows purification by chitin binding
chromatography. Subsequently after cloning and protein expression, thiol-induced
cleavage of the intein released the His6-cb5 protein that was further purified by standard
Ni-NTA column chromatography.

Site-Directed Mutagenesis of the non-canonic CTG codon in C. albicans CBR1
In C. albicans, the CTG codon that normally encodes the amino acid leucine is
translated as a serine [49-53]. In the C. albicans CBR1 gene, there is one occurrence of
this non-canonic codon usage at amino acid position 78. In order to accurately
characterize the properties of the Cbr1 protein, site-directed mutagenesis was performed
by designing specific primers that mutate the ‘CTG,’ normally transcribed as leucine, to
‘TCG,’ which encodes serine. Following transformation of the vector containing the
Leu78  Ser78 mutagenesis, a positive clone was sequenced to confirm the mutation.
The C. albicans MCR1 and cb5 genes do not have CTG codon usage, and
therefore site-directed mutagenesis of the non-canonic serine codon was not necessary.
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Table 1. Primers used in the construction of the C. albicans cb5r protein expression
system.
Restriction endonucleases (EcoRI and XhoI) are underlined in the first two primers, and
affected codons in the site-directed mutagenesis of Leu78Ser are underlined in the last
two primers. The His6- encoding sequence is shown in italics. Start and stop codons are
bolded.
Protein
cloned:

to

be

Sequences:


Full-length
CBR1

∆Threonine-45
CBR1





CBR1 Leu78 
Ser 78 sitedirected
mutagenesis
(codon
is
underlined and in
bold)





Full-length cb5
(to be cloned
into pET-23b)



CalbCytb5Red-Fwd (with EcoRI site):
5’-TAGCTAGAATTCATGTCTGAAACTACTACTGTTCCTCC-3’
CalbCytb5Red-Rev (with XhoI site):
5’-GTCATACTCGAGTTAAAAGACAAACACTTGATCACCCAAT-3’
CalbCytb5Red-His6-T45-Fwd (with EcoRI site and His6 tag):
5’TAGCTAGAATCCATGCACCATCACCATCACCATATGACCCCAGTTT
TAAAACCAGATGAATTTC-3’
CalbCytb5Red-Rev (same as full-length)
CalbCb5r-L78S-Fwd
5’-TGGTTTACCAAAATCGACTGATAGATTAGG-3’
CalbCb5r-L78S-Rev
5’-ATCCTAATCTATCAGTCGATTTTGGTAAACCAAATC-3’

CalbCytb5-Fwd (with EcoRI site):
5’-TAGCTAGAATTCATGTCAGAAGAAACCGTTACTATTTAC-3’
CalbCytb5-Rev (with XhoI site):
5’-GTCATACTCGAGTTAAGCAAAGTTAGTTTTGTAATAATAAG-3’

∆Glycine-101
cb5 (to be cloned
into pET-23b)




CalbCytb5-Fwd (same as full-length)
CalbCytb5-His6-G101Rev (with XhoI site and His6 tag):
5’GTCATACTCGAGTTAATGTGATGGTGATGGTGACCACTATCTTCAG
TAGCATAAGATTG-3’

∆Glycine-101
cb5 (to be cloned
into pTWIN1)



CalbCytb5pTWIN1-Fwd (with NdeI site):
5’-TAGCTACATATGTCAGAAGAAACCGTTACTATTTACG-3’
CalbCytb5-His6-G101pTWIN1-Rev (with SapI site, PCR performed with
∆G101-His6-Cb5 DNA, so His6-tag already present):
5’-CAGTATGCTCTTCTGCAATGGTGATGGTGATGGTGACCACTA-3’

∆Threonine-46
MCR1







CalbCbr1Mcr1-His6-T46-Fwd (with EcoRI site and His6 tag):
5’TAGCTAGGATCCATGCACCATCACCATCACCATATGACTTTCACTGA
TAGCAATGAATGGGTGG-3’
CalbCbr1Mcr1-Rev:
5’- GTCATACTCGAGCTAAAATTTAAAGACATGTTCTTTTTCG-3’
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Recombinant protein optimization of expression and purification
Cultures of E. coli BL21 (DE-3) RIPL cells containing the plasmid expressing C.
albicans Cbr1 or Mcr1 were grown in Terrific broth containing 75 μg/mL of ampicillin
(for selection by antibiotic resistance) and 100μM riboflavin (critical for incorporation of
the FAD prosthetic group) to mid-log phase (OD600 = 0.5-0.8), and recombinant protein
expression was induced with 0.2mM IPTG and grown 16 hours at 23 °C. The cells were
then harvested by centrifugation at 5,000 rpm for 10 minutes at 4 °C, washed with PBS,
and resuspended in lysis buffer containing 50 mM Tris-HCl, 300 mM NaCl, and 10 mM
imidazole, pH 8.0. Cells were sonicated in the presence of 50 μM PMSF protease
inhibitor, followed by centrifugation (2,500 rpm for 20 minutes at 4 °C) to obtain the
soluble cell fraction. Subsequently, cell lysate supernatant was incubated with Ni-NTA
agarose for 1 hour at 4 °C, followed by centrifugation to collect the protein-His6-Ni-NTA
matrix suspension, washed with lysis buffer, and transferred to a chromatography
column. Bound protein was collected by elution with 250 mM imidazole in a 50 mM
phosphate buffer containing 300 mM NaCl. The elutions were concentrated by
ultrafiltration using Amicon Ultra-4, 10,000 MWCO (Millipore Corp) and further
purified by size exclusion chromatography using Superdex 75 gel filtration resin.
Fractions containing the purified protein were concentrated by ultrafiltration, and
“beaded” by pipetting droplets of concentrated enzyme solution into liquid nitrogen.
Sodium dodecyl sulfate-polyacylamide gel electrophoresis (SDS-PAGE) was performed
to confirm optimization of expression and purity of the Cbr1 protein
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Protein Homology Modeling
The predicted structure of the C. albicans Cbr1 and Mcr1 proteins were generated
using the automated comparative protein modeling server SWISS-MODEL. Using this
automated approach, the web server analyzes the target sequence alignment to a template
protein structure already found in the UniProt database, and for both C. albicans proteins,
rat cb5r complexed with NAD+ (PDB ID: 1IB0) was used as template.

UV/Vis Absorbance Spectroscopy
UV/visible spectra were obtained using a HP (Agilent Technologies, Palo Alto,
CA) 8453A diode-array spectrophotometer utilizing micro-cuvettes of 200 μL capacity
and with 1 cm path length.
.
Initial-Rate Enzyme Kinetics
Enzyme activities were determined at 25 °C under conditions of constant ionic
strength and pH in 116 mM MOPS buffer containing 0.1 mM EDTA, pH 7.0. NADH :
FR activities were typically determined as the decrease in absorbance at 340nm in the
presence of NADH substrate (1-200μM) and 200μM ferricyanide (FR). Initial rate data
were analyzed using the software “ENZFIT” (Elsevier Biosoft, Ferguson, MO) and
KaleidoGraph to yield apparent kcat, Vmax, and Km values.
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UV/Vis Circular Dichroism
UV and visible circular dichroism (CD) spectra were performed using a JASCO
(Easton, MD) J710 spectropolarimeter in 10 mM phosphate buffer. Protein samples were
assessed for concentration and purity prior to the assay, and were confirmed by SDSPAGE analysis. UV CD spectra were obtained in 10 mM phosphate buffer, containing
0.1 mM EDTA, pH 7.0 using a cylindrical quartz cell of 0.1 cm path length (360 μl total
volume) while visible CD spectra were obtained in 10mM MOPS buffer, containing 0.1
mM EDTA, pH 7.0 using a 1 cm path length cell (120μl total volume). All spectra were
corrected for the appropriate buffer contributions and are expressed in terms of molar
ellipticities (M-1 cm-1).

The DICHROWEB analysis web server was used in CD

deconvolution and secondary structure analysis.

Thermal Stability Assays

Fluorescence Spectroscopy
In order to monitor the release of the FAD prosthetic group correlating to increase in
temperature, fluorescence spectra were performed using a Shimadzu (Columbia, MD)
RF-2501PC spectrofluorometer. Excitation and emission spectra were obtained using a
slit width of 3 nm and emission and excitation wavelengths of 520 nm and 450 nm,
respectively.
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Determination of T50
To determine the T50 values, protein samples in 50 µM phosphate buffer containing 0.1
mM EDTA, pH 7.5 were initially incubated at 0 °C for 5 minutes, followed by
subsequent 5 minute incubations at 5 °C interval increases. After each temperature
interval, an aliquot of sample was removed, diluted in ice-cold phosphate buffer and
assayed for enzymatic activity. Data was plotted as relative to the initial enzyme activity
at 0 °C in terms of relative fluorescence (denoted by free FAD) against the increase in
temperature.

Thermodynamic Analysis
To determine the activation energy, protein samples were incubated at stepwise
temperatures ranging between 22 and 28 °C, and subsequently assayed for catalytic
activity as previously described. These data were then used to construct an Arrhenius plot
to deduce activation energy by plotting the logarithmic rate against inverse temperatures.

Kinetic Inhibition Assays
Enzyme activities were determined at 25 °C under conditions of constant ionic
strength and pH in 116 mM MOPS buffer containing 0.1 mM EDTA, pH 7.0. In the
substrate and ADP analogues inhibition assays, 100 μM NADH substrate concentration
and 5 mM inhibitor concentration was utilized. To create the double reciprocal plots used
in determination of Ki values, NADH substrate concentrations of 6, 10, and 100 μM were
used, as well as various concentrations of the inhibitor ranging from 0.5 to 5.0 mM. The
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values were then plotted in SigmaPlot, followed by regression analysis to determine
apparent Km values for each concentration of inhibitor assayed.

Yeast Growth Curves
Growth of C. albicans in the Presence of Potential Inhibitors
C. albicans strain SC5314 was grown in YEPD liquid media (Bio101, Inc.) or
YPD agar (Difco) at 30 °C for 16-24 hours. High density overnight cultures were diluted
to early to mid-log phase (indicated by OD600) and allowed to recover before the addition
of inhibitor (Rotenone: 2–100 μM; Alachlor: 5-50 μM; Paraquat: 1-10 mM).

Cell

densities were recorded over a 24-hour period to calculate doubling times.

S. cerevisiae Knockout Strains Growth in the Presence of Various Environmental
Stressors and Selected Antifungal Agents
S. cerevisiae BY4742 wild-type parental strain and knockout strains were grown
in YEPD liquid media at 30°C for 16-24 hours. In the environmental stressor assays, high
density overnight cultures were diluted to early to mid-log phase (indicated by OD600)
and allowed to recover for approximately one doubling time before the addition of the
selected environmental stressor. Oxidative stress assays were performed in the presence
of 0.5% and 2.0% hydrogen peroxide, and acidic environmental conditions mimicking
that of the lysosomal pH were created using 25mM MES. 5mL and 25mL cultures were
grown for 24 hours and cell densities were observed as indicated by the measurement of
the OD600 every 1-2 hours.
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For the antifungal compounds assays, inhibition was observed through a halo
assay using sterile Whatman filter disks containing the appropriate antifungal compound
added to agar plates. Specifically, high density overnight cultures were diluted to 300,000
cells in 5mL fresh YEP media, and subsequently added to 0.7% YEPD top agar media,
vortexed thoroughly and added to sterile YEPD agar plates. Plates were allowed to dry
for approximately one hour before adding the selected antifungal compounds. A one-hole
puncher apparatus was used on Whatman filters, and the “Whatman circles” were
subsequently autoclaved in a glass Petri dish. Antifungal compounds (resuspended and
diluted in DMSO) were added to the “Whatman circles” and allowed to dry slightly
before using sterile tweezers to transfer them to the agar plates containing the indicated S.
cerevisiae strain.

Sterol Analysis
A single colony of S. cerevisiae wild-type and knockout strains was inoculated
into 50mL YEPD media and allowed to grow overnight (16-20h) at 30 ºC. Cells were
harvested by centrifugation at 2700 rpm for 5 minutes, washed with 10mL sterile distilled
water, and centrifuged again. Net weight wet of the pellets were recorded at this point.
3mL of 15% KOH in 90% (vol/vol) ethanol was added to each pellet, transferred to
sterile glass tubes, and vortexed vigorously for one minute, followed by incubation in an
85 ºC water bath for one hour. Tubes were allowed to cool to room temperature for
approximately 30 minutes. The sterols were then extracted by addition of 1mL water and
3mL n-heptane followed by vigorous vortexing for 3 minutes. The organic heptane (top)
layer was then transferred to a fresh glass tube and stored at -20 ºC for up to one day.
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UV spectral analysis ranging from 230nm to 330nm was performed using the
Synergy Mx Multi-Mode Reader (Biotek, Winooski, VT) and visualized with Gen5 data
analysis software (Biotek). Ergosterol content was calculated using the ArthingtonSkaggs sterol quantitation method (SQM), in which UV absorbance spectra are used to
quantitate ergosterol and DHE sterol content [54]. Both ergosterol and DHE absorb at
281.5nm, whereas only DHE absorbs at 230nm [22]. The ergosterol content is calculated
as a percentage of the net wet weight of the cell by the following equations:

% Ergosterol + DHE = [(A281.5nm/290) x F] / pellet weight
% DHE = [(A230nm/518) x F] / pellet weight
% Ergosterol = (% Ergosterol + DHE) - % DHE

where F is the dilution factor in heptane, and 290 and 518 are the E values (in percent per
centimeter) determined for crystalline ergosterol and DHE, respectively [54].

Protein:Protein Interactions
C. albicans Spheroplasts
C. albicans spheroplasts were created by growing overnight high-density yeast cells
(15mL cultures per protein interaction sample). Cells were harvested by centrifugation
for 10 minutes at 2,500 x g, washed twice with 5mL sterile deionized water and once
with 5mL 1M sorbitol, centrifuging as above. The cells are then resuspended in 2mL
“Buffer 1,” containing 1M sorbitol, 50mM DTT, and 25mM EDTA (pH 8.0), and
incubated at 30°C for 10 minutes with rotation. From this point in the experiment, the
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centrifuge temperature was reduced to 4°C and cells were kept on ice in between washes.
After washing twice with ice-cold 1X PBS, cells were then resuspended in 1mL “Buffer
2,” containing 1M sorbitol, 0.1M sodium citrate (pH 5.8), 10mM EDTA, 10μL
mercaptoethanol, and 0.1mg Zymolyase-100T, and incubated at 30°C for 30 minutes
with rotation. Cells were then sonicated three times for 30 seconds each, using an OmniRuptor 250 ultrasonic homogenizer (Omni, Kennesaw, GA) with 40% power and 50%
pulsar settings. Spheroplasts were then collected by ultracentrifugation for 10 minutes at
10,000 x g at 4°C.

His6-tagged Protein Pull-Down Assay
150μg recombinant His6-tagged C. albicans Cbr1 was incubated with 500μL C. albicans
cell lysate (spheroplasts) for one hour at room temperature with rotation.

The

cytoplasmic conditions were mimicked by using physiological osmolarity (TBS buffer)
and 40 mM DTT to create a reducing environment. 400μM DMS crosslinker
(resuspended in 0.2M triethanolamine) was added to desired samples after the first 15
initial minutes of the cell lysate: Cbr1 protein incubation. The reactions were stopped
after one hour by the addition of 25μL of 1M Tris to the samples. After incubation of
His6-tagged Cbr1 with cell lysate, the mixture was incubated with Ni-NTA resin for 60
minutes at 4°C using end-over-end rotation to immobilize the protein complexes.
Following washing of the resin five times by centrifugation with proprietary lysis buffer
(Pierce), bound proteins was collected by elution with 150μL 290 mM imidazole in a
phosphate buffer containing TBS.
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Mass Spectroscopy and Analysis
SDS-PAGE analysis was performed using 4-20% gradient gels in BupH running buffer
(Pierce) containing 0.1 M Tris, 0.1 MHEPES, 3 mM SDS, pH 8.0. Bands were excised
and sent to the IDRB Proteomics Core Facility (Tampa, FL) for mass spectrophotometric
analysis. Results were viewed and analyzed using Scaffold proteome software to identify
proteins potentially interacting with the C. albicans Cbr1 recombinant protein.
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3. RESULTS AND DISCUSSION

I. EXPRESSION AND BIOCHEMICAL CHARACTERIZATION OF C. ALBICANS CBR1 AND
MCR1 C5R ISOFORMS
C. albicans cb5r constitutes an attractive novel drug target due to its role in the
metabolism of xenobiotics and other important biological processes such as ergosterol
biosynthesis. Phylogenetic analysis revealed two distinct clades of mammalian and
fungal cb5r, respectively (Figure 6). While mammalian cb5r has been well characterized,
nothing is known about the enzymatic properties of cb5r in pathogenic fungi. Using rat
cb5r as a mammalian control, recombinant C. albicans cb5r will be used to characterize
the kinetic, biochemical, and pharmaceutical properties of the fungal protein in
comparison to its mammalian counterpart. Hence, in the first aim (Chapters I and II) I
have tested the hypothesis that C. albicans cb5r differs from mammalian cb5r in its
kinetic, biochemical, and pharmacological characteristics.
Phylogenetic analysis was performed to evaluate the evolutionary distance
between the cb5r and cb5 protein sequences of different species, ranging from fungi to
mammals (Figure 6). A distinctly separate clade was found for fungal cb5r that separates
it from mammalian cb5r. In the phylogenetic analysis it was also observed that the fungal
cb5r CBR1 isoforms are most closely related to plant cb5r. A recent patent lists plant cb5r
as a potential herbicidal target, making these plant inhibitors promising candidates as a
new class of antifungals against Candida cb5r . An interesting finding was that the fungal
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mitochondrial MCR1 isoform formed an independent clade separate from the fungal
CBR1 isoform, located predominantly in the ER.

Figure 6: Phylogenic Analysis and Sequence Similarity of Rat
and C. albicans Cb5r
(A) Phylogram of Cytochrome b5 Reductases and Cytochrome b5.
Amino acid sequences of cb5r (left) and cb5 (right) were aligned using ClustalW.
Fungal cb5r CBR1 isoforms formed a distinct clade having the closest sequence
similarity to plants, and all fungal isoforms were distinct from their mammalian
orthologues. Fungal cb5 proteins also formed a distinct clade from mammalian
cb5.
(B) Sequence Alignment of Rat Cb5r and C. albicans Cbr1.
Amino acid sequences were aligned using UniProt (Rat cb5r: P20070; C. albicans
Cbr1: Q59P03). Amino acid identity (115/294aa = 39.1%) and similarity
(215/294aa = 73.1%).
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Structural comparison between mammalian and fungal cb5r was then performed
using crystallographic and in silico data analysis (Figure 7A). The ribbon diagram of rat
cb5r based on the crystal structure is shown with the FAD prosthetic group (blue) and
substrate NADH (yellow). Currently there is no crystal structure of the C. albicans cb5r
and therefore this protein was modeled in silico using homology to the rat cb5r sequence.
Two major structural differences between fungal and mammalian cb5r were predicted: (1)
the less stable hinge region between the NADH and FAD binding sites in C. albicans that
contains only one β-sheet, in contrast to three β-sheets in rat cb5r and (2) the absence of a
protective lid covering the FAD prosthetic group in C. albicans that is found in rat cb5r
(Fig. 2A). Subsequently, ClustalW alignment was used to compare the amino acid
sequences of mammalian and fungal cb5r, and particular attention was given to the four
conserved binding motifs for NADH substrate binding and FAD prosthetic group (Figure
7B). Of particular interest are two large 9- and 16- amino acid gaps in all fungal
sequences before the FAD/FMN selectivity motif and the first NADH binding motif,
respectively, that represent the missing lid covering the FAD prosthetic group and the
missing β-sheets in the hinge region connecting the two catalytic domains (Figure 7).
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Figure 7: Structural Comparison of Mammalian and Fungal Cb5r.
(A) The ribbon model of rat cb5r based on the crystal structure is shown with the
FAD prosthetic group (blue) and substrate NADH (yellow). C. albicans cb5r Cbr1
was modeled in silico. Note the differences in the hinge region between the NADH
and FAD-binding domains that is lacking in C. albicans cb5r, as well as the absence
of the lid covering the FAD prosthetic group.
(B) Amino acid sequence alignment by ClustalW analysis was performed
comparing the mammalian and fungal cb5r conserved motifs. One difference in the
second amino acid position is observed between human and C. albicans Cbr1 (Pro
→ Ser) in the flavin binding motif. The first NADH binding motif has the signature
sequence GxGxxP. The mammalian sequences are all GTGITP, whereas C.
albicans Cbr1 has GTGIAP, with a Thr-to-Ala substitution. Note the 9-amino acid
gap preceding the FAD/FMN selectivity motif in all fungal Cbr1 and Mcr1
isoforms (i.e. lid covering the FAD prosthetic group, Fig. 2A). Similarly, the 16amino acid gap before the first NADH binding motif in all fungal cb5r isoforms
reflects the two missing β-sheets in the C. albicans Cbr1 hinge region (Fig. 7A).

To confirm the primary structure of the fungal cb5r isoforms, Cbr1 and Mcr1, as
well as to compare and contrast the functional properties of recombinant enzyme with
those of the mammalian rat enzyme, the genes encoding both proteins were cloned,
expressed and characterized. Multiple sequence alignments were performed between the
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online genome resources (CGD, SGD, and NCBI) to confirm the primary sequence of
each of the isoforms for subsequent cloning. The genes encoding CBR1 and MCR1
(lacking the N-terminal transmembrane domain) were cloned from C. albicans genomic
DNA into the pET-23b protein expression vector system. The genes were subsequently
transformed into E. coli BL21 (DE3) RIPL cells for use in large-scale protein expression
and purification of C. albicans ∆T45-His6-Cbr1 and ∆T46-His6-Mcr1. Addition of
riboflavin to the bacterial culture medium, Terrific broth (TB), is critical for expression
of active cb5r enzyme with incorporated flavin as the prosthetic group. Optimization of
protein expression revealed that the optimal growth conditions are overnight (16 h)
culture at room temperature (23 °C) after being induced with 0.2 mM IPTG. Upon
sonication of the induced bacterial cell pellet, ∆T45-His6-Cbr1 localized in the cell lysate
supernatant and protein purification using Ni-NTA chromatography and subsequent size
exclusion chromatography revealed successful purification of the ∆T45-His6-Cbr1
recombinant protein (28.7 kDa, Figure 8) as well as the OMM isoform, ∆T46-His6-Mcr1
(29.8 kDa), for use in the biochemical and kinetic analyses. Large-scale protein
purification of the Cbr1 isoform yielded recombinant protein at a concentration of ~10.4
mg/L (250 μL of 200 μM C. albicans Cbr1, Table 2).
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Figure 8. Purification of C. albicans Cbr1 and Mcr1 Recombinant Proteins. Bacterial
cultures expressing C. albicans Cbr1 (16 h culture at 23 °C induced with 0.2 mM IPTG)
were lysed by sonication (3x 20 sec on ice) followed by centrifugation to separate pellet
(P) and supernatant (S/N). Our results indicate that the Cbr1 protein (His6-tagged) is
soluble and localized in the cell lysate supernatant. Further purification was achieved by
Ni-NTA column chromatography of the cell lysate supernatant followed by size
exclusion chromatography (SEC). C. albicans Mcr1 recombinant protein was expressed
and purified in the same manner, and SEC-purified Mcr1 protein is shown. Rat cb5r
purified recombinant protein is shown as a control. A red asterisk indicates the 28.7 kDa
Cbr1 protein in the induced and supernatant lane samples.
SDS-PAGE analysis using 4-20% acrylamide gradient gels in a Tris-HEPES-SDS
buffer system.

Table 2. Purification of Recombinant C. albicans Cb5r Cbr1 Protein
(4 liters of bacterial culture).
Specific Activity
Total
Total Activity
(μmol
Volume
(mmol
Protein
(mL)
NADH/min/mg
(mg)
NADH/min)
protein)
Total cell lysate 299
50
301.93
1.01
Supernatant
203
50
253.70
1.25
Ni-NTA eluant 6.7
10
201.61
30.09
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Due to the small size of the C. albicans ∆G101-His6-cb5 protein (11.2 kDa),
purification using the pET-23b vector followed by Ni-NTA did not succeed in a
significant yield of purified product. Therefore, this protein was successfully expressed
using the IMPACT-TWIN vector, pTWIN1 (NEB, Figure 9). In this method, the target
gene is cloned adjacent to a DNA sequence encoding an intein endoprotease (thiol
inducible) linked to a chitin binding domain (CBD) that allows purification by chitin
binding chromatography. Subsequently, thiol-induced cleavage of the intein released the
His6-cb5 protein that was further purified by standard Ni-NTA column chromatography
(Figure 10).

Figure 9. IMPACT-TWIN vector schematic used in purification of C.
albicans cb5.
C. albicans cb5 was cloned into the pTWIN1 vector system that allows
purification of recombinant proteins through chitin binding chromatography.
The gene is cloned adjacent to a DNA sequence encoding a thiol-inducible
intein endoprotease linked to a chitin binding domain. 40mM DTT was used
to activate the intein2 endoproteinase actvitiy and allow cleavage of the His6tagged-cb5 protein that was further purified by Ni-NTA column
chromatography (Adapted from New England Biolabs, Inc.).
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Figure 10. Purification of C. albicans cb5 Recombinant Protein. C. albicans
cb5 samples (16 h culture at 23°C) were lysed by sonication (3x 20 sec on ice)
followed by centrifugation to separate pellet (P) and supernatant (S/N). Our results
indicate that the cb5 protein (CBD/intein-tagged and His6-tagged) is soluble and
localized in the cell lysate supernatant. Further purification was achieved by chitin
binding chromatography followed by Ni-NTA column chromatography of the cell
lysate supernatant.
SDS-PAGE analysis using 4-20% acrylamide gradient gels in a Tris-HEPES-SDS
buffer system.

Following purification of the C. albicans Cbr1 protein, UV/visible spectral
analysis was performed and compared to the spectra previously obtained from rat,
human, and canine cb5r. Both rat enzyme and C. albicans Cbr1 display similarities in the
UV absorption spectra, with the absorption maximum detected at 273nm. However, the
fungal enzyme exhibited a peak at approximately 458nm, in contrast to the rat cb5r with a
peak at 461nm, both enzymes having the associated pronounced shoulder at 480nm
(Figure 11). This peak in the visible spectrum at approximately 461nm is attributable to
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the protein-bound flavin; if the prosthetic group is not bound to the protein, it would
instead display a singular peak at 450nm, indicating free flavin and thus non-functional
protein. The concentration of the protein is determined by using the Beer-Lambert law,
observing absorance at 461nm divided by 10.6 M-1 cm-1, the extinction coefficient of cb5r
enzyme. Purity of the enzyme is determined by the ratio of optical density at 272nm to
461nm, with optimal results of 6-7; a ratio of up to 14 has been found to display similar
kinetic activity to pure enzyme. For assays requiring high levels of purity, such as
structure analysis, a purity ratio no higher than 7.0 was deemed acceptable. Therefore,
after every large-scale protein purification, UV/visible absorption spectra are performed
to confirm the presence of functional protein and purity for use in the later enzymatic
assays.

Figure 11. Spectral Analysis of C. albicans and Rat Cb5r.
Spectrophotometric analysis of UV and visible absorption spectra for recombinant C.
albicans Cbr1 and rat cb5r (representative of each protein) is shown. The active enzymes
have a characteristic peak at 457 nm (Candida) and 461 nm (rat) with a shoulder at 480
nm that is absent in inactive enzyme, which lacks the protein-bound flavin.
37

Initial-rate enzyme kinetic analysis was performed for the C. albicans Cbr1
protein to determine the substrate binding affinity (KmNADH) and catalytic rate (kcat) of the
recombinant protein. The C. albicans Cbr1 enzyme displayed a KmNADH of 6.0 ± 0.5 µM
(Fig. 3), identical to the rat cb5r KmNADH of 6.0 µM (Figure 12). However, the fungal
enzyme had a decreased Vmax and kcat (28.2 ± 0.5 µmol/min/nmol FAD and 460 s-1,
respectively), in comparison to the rat cb5r (48 µmol/min/nmol FAD and 800 s-1,
respectively).

Figure 12. Initial-Rate Enzyme Kinetics of Recombinant C. albicans Cbr1.
Enzyme kinetics were determined using NADH (at various concentrations) as
the electron donor and ferricyanide (200µM) as the artificial electron acceptor
yielding an apparent KmNADH of 6.0 ± 0.5 µM (analysis by Enzfitter and
KaleidaGraph, r = 0.9939; n = 6).

Initial-rate enzyme kinetic analysis was also performed for the C. albicans Mcr1
protein to determine the substrate binding affinity (KmNADH) and catalytic rate (kcat) of the
recombinant protein. The C. albicans Cbr1 enzyme displayed an increased affinity for
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the NADH substrate as compared to the rat cb5r and C. albicans Cbr1, having a KmNADH
of 5.1 ± 0.8 µM (Figure 12). However, the fungal Mcr1 enzyme had a decreased Vmax
and kcat (28.2 ± 0.5 µmol/min/nmol FAD and 460 s-1, respectively) that was similar to the
Cbr1 isoform, both functioning at almost half of the catalytic turnover rate of the rat cb5r
(Figure 13; 48 µmol/min/nmol FAD and 800 s-1, respectively). The Michaelis-Menten
kinetic analysis for all three proteins is also shown below in Table 3.

Figure 13. Initial-Rate Enzyme Kinetics of Recombinant C. albicans Mcr1.
Michaelis-Menten kinetics for substrate saturation kinetics of C. albicans Mcr1 uptake
rate was measured at various concentrations of NADH. Kinetic values of Km = 5.07 ±
0.77 µM and a Vmax = 28.87 ± 0.85 µmol/min were deduced from the data using the
KaleidoGraph analysis. (r = 0.9897; n = 3-6).
Insert: Hanes plot transformation of the data showed a linear line, illustrating that the
Mcr1 enzyme has a single enzymatic reaction center.
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Table 3. Comparison of Initial-Rate Enzyme Kinetics of
Rat and C. albicans cb5r Proteins.
kcat
KmNADH
kcat /KmNADH
Vmax
-1
-1
-1
(s )
(μM)
(s M )
(µmol/min/nmol FAD)
Rat

800

6.0 ± 1.1

13.3 x 107

48.0 ± 0.6

Cbr1
Mcr1

460
482

6.0 ± 0.5
5.1 ± 0.8

7.7 x 107
9.5 x 107

28.2 ± 0.5
28.9 ± 0.9

Thermal stability assays were performed to measure protein stability between the
rat cb5r and C. albicans Cbr1 proteins. To determine the T50 value, the assay monitors the
release of the FAD prosthetic group as shown by the increase in fluorescence indicating
free flavin, as well as the loss of enzymatic activity by the generation of thermal
denaturation profiles.

Hence, T50 values are generated, which correspond to the

temperature at which 50% of enzymatic activity is retained. C. albicans Cbr1 exhibited a
T50 value of approximately 44°C, in contrast to the rat cb5r T50 value of 55°C (Figure
14A). This may reflect the structural difference of only one β-sheet in the hinge region of
the fungal enzyme compared to three β-sheets in the mammalian enzyme that may
account for less structural stability (Figure 7A).
Thermodynamic measurements and determination of activation energy was
performed by observing the differences in catalytic rate at various temperatures followed
by Arrhenius plot analysis. The activation energy of C. albicans Cbr1 was found to be
significantly decreased (Ea = 27.5 ± 1.2 kJ/mol) in comparison with the rat enzyme (Ea =
35.9 ± 5.2 kJ/mol; Figure 7B). Again, this decreased thermal stability may be attributed
to the lack of hinge region in C. albicans Cbr1, as compared to the more pronounced
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hinge region connecting the NADH and FAD-binding domains in the mammalian
enzyme.

Figure 14. Thermal Stability and Thermodynamic Analysis of Rat Cb5r and C.
albicans Cbr1.
(A) In contrast to the rat cb5r T50 value of 55 ºC, the C. albicans Cbr1 protein exhibited a
significantly decreased T50 of approximately 44 ºC. The decreased stability of the fungal
protein may be due to the lack of hinge region connecting the two catalytic domains of
the protein (Fig. 1A)(n = 1).
(B) The activation energy of C. albicans Cbr1 was found to be significantly decreased (Ea
= 27.5 ± 1.2 kJ/mol) in comparison with the rat enzyme (Ea = 35.9 ± 5.2 kJ/mol)(n = 3).
Circular dichroism spectroscopy was performed to compare the secondary structure
analyses as well as the flavin-binding environment of the rat cb5r and C. albicans Cbr1.
The CD spectral analysis comparing rat and C. albicans proteins in the UV range (190-300
nm) revealed only small differences in secondary structure composition (Figure 15),
presumably due to folding differences. The molar ellipticity data generated were then
transferred to a deconvolution web server, DICHROWEB, to compare secondary structure
composition between the rat and C. albicans enzymes, and this information supported the
CD spectra that no significant differences were observed (Table 4). CD spectroscopy and
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DICHROWEB analysis to compare secondary structure composition were performed in the
presence of NADH to determine if there is a structural change that occurs in the C. albicans
Cbr1 upon substrate binding. The analysis revealed an increase in α-helices and a decrease
in β-turns upon addition of NADH, suggesting that a conformation change does in fact
occur (Table 4). In the visible range (300-600 nm) that provides observations into the
flavin-binding environment, C. albicans cb5r had a similar spectral intensity at the negative
CD maxima when compared to the rat CD maxima, as well as the characteristic shoulder at
480nm (Figure 15).

Figure 15. Circular Dichroism Spectroscopy Comparing Rat Cb5r and C. albicans
Cbr1. Only minor differences were observed between the rat and fungal proteins in the
UV range (190-300 nm). This was further supported by the DichroWeb analysis used in
deconvolution of secondary structure composition (Table 4). The flavin-binding
environment in the visible range (300-600 nm) revealed almost identical spectra, as well
as the characteristic shoulder at 480 nm (n=3; figure above is representative).
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Table 4: DICHROWEB Analysis of Secondary Structure Composition between
Rat and C. albicans cb5r Proteins.
Protein

Modification

αHelices

β-Turns

Rat cb5r

-----------------------

0.046

0.229

C.
albicans
Cbr1

-----------------------

0.054

0.251

C.
albicans
Cbr1

With
substrate

0.096

0.108

NADH

LIGPLOT analysis was also utilized in order to examine the differences in FAD
ligand binding between mammalian and fungal cb5r proteins. Since the crystal
structure of rat cb5r has been solved (PDB 1IB0), we are able to examine the
interactions of the amino acids that are involved in interactions with the FAD
prosthetic group. In order to compare the fungal enzyme’s ligand binding properties,
sequence alignment was performed to compare the substitutions and/or deletions
between the two proteins. Rat cb5r has 11 hydrogen bonds and 10 hydrophobic
interactions with the FAD ligand (Figure 16). In C. albicans Cbr1, there are six
differences in amino acid residues, including five substitutions and one deletion.
There are also four differences in hydrophobic interactions, two amino acid
substitutions and two deletions. Interestingly, the three deletions that occur are within
the sequence of the “lid” covering the FAD prosthetic group that is present in the
mammalian enzyme but lacking in its fungal counterparts.

Several of the

substitutions between the rat and fungal enzymes are present surrounding the tricyclic
isoalloxazine ring (Figure 16, shown in red) of the flavin moiety. The isoalloxazine
ring is responsible for the optical activity apparent in the visible range, and these
amino acid differences between fungal and mammalian enzymes involved in ligand
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binding may account for the slight shift from 461nm in rat to 457nm in C. albicans
Cbr1.

Figure 16. LIGPLOT Analysis of Rat cb5r and C. albicans Cbr1 Interactions with
the FAD Prosthetic Group.
Rat cb5r (PBD 1IB0) LIGPLOT analysis of protein : FAD interactions reveals 11
hydrogen bonds and 10 hydrophobic interactions between the protein and ligand. In C.
albicans Cbr1, 6 hydrogen bond amino acid residues (circled in red) were found, with 5
substitutions and one deletion at Phe113. In the fungal enzyme, there were also 4
differences in hydrophobic interactions (circled in black), accounting for two
substitutions and two deletions at His117 and Phe120.
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The preceding results indicate the first detailed examination of cb5r as a potential
novel drug target in a pathogenic fungus such as Candida albicans. Using sequence
homology results obtained from the Saccharomyces and Candida Genome Databases
(SGD and CGD, respectively), we were able to clone the predominately ER-located cb5r
isoform, CBR1, from C. albicans genomic DNA and subsequently produce large-scale
recombinant protein expression and purification. We also cloned the cb5r isoform
predominantly located in the outer mitochondrial membrane, MCR1, and performed
large-scale recombinant protein expression and purification. Using purified recombinant
protein, we were able to compare the kinetic and biochemical characteristics of C.
albicans Cbr1 as compared to rat cb5r, its mammalian counterpart.
Because of its role in the metabolism of drugs and other xenobiotics, as well as its
important role in other biological processes such as ergosterol biosynthesis, the C.
albicans cb5r proteins are attractive candidates for fungal drug development. In fact,
enzymes of the CYP family, including many of the cytochrome P450 reductases involved
in ergosterol biosynthesis, have been prime targets for antifungal therapeutics. Although
other enzymes in this pathway have been investigated as potential drug targets, fungal
cb5r has not been characterized against its mammalian counterpart for preliminary
examination prior to its possibility in drug development.
Although both enzymes displayed similar substrate affinity to NADH, the
physiological electron donor, the fungal enzymes displayed a significantly decreased
catalytic turnover of almost 50% less than the rate of rat cb5r. C. albicans Cbr1 also
proved to be less thermodynamically stable in both T50 experiments as well as in
determination of the activation energy by Arrhenius plot analysis. To interpret the
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difference between rat and yeast enyzmes you must first establish that the rat and yeast
enzymes are comparable in quantity and quality. These differences in thermal stability
and catalytic rate may in part be due to the key differences in structure between the
mammalian and fungal proteins. The lack of β-sheets connecting the two catalytic
domains as well as the lid covering the FAD prosthetic group may account for less
stability in the fungal enzyme, without having any noted effects on substrate affinity.
Mutations observed in the hinge region connecting the two catalytic domains also
show decreased thermal stability and catalytic activity when investigated in the rat cb5r
model [55]. Three mutations, P144L, L148P, and R159*, that are linked to recessive
congenital methemoglobinemia in humans are located in the hinge region, and these
mutations were generated in rat cb5r to characterize their spectroscopic, kinetic, and
thermodynamic properties. Although spectrally indistinguishable from wild-type enzyme,
the mutant enzymes P144L and L148P exhibited only about 30% enzymatic activity and
2-5 ºC decreased Tm values when compared to wild-type cb5r. The R159* mutant was
unable to be purified, as anticipated due to the premature stop codon and loss of the
NADH binding domain. In C. albicans cb5r, the first proline residue P144 is unchanged,
although the second residue is substituted L148F, followed closely by the 16-amino acid
gap present in all fungi which accounts for the shortened hinge region between the FAD
and NADH binding domains. Davis et. al. hypothesize that the significant effects on
kinetic activity and thermal stability could be explained by the altered spatial registration
between the two catalytic domains [27].

This hypothesis is further supported by

characterization of cb5r in the slime mold Physarum polycephalum, where investigators
found that enzymatic activity decreased rapidly above 50 ºC [56], in comparison to the
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relatively stable human enzyme. Again, the researchers hypothesize that the decrease in
thermal stability is attributed to the lack of two β-sheets in the hinge region.
Structural comparisons of the C. albicans Cbr1 and Mcr1 protein were predicted
using in silico analysis, although the crystallographic structures of the proteins are
necessary for confirmation. It will allow us to further investigate the differences in the
hinge region connecting the catalytic domains of cb5r that may be a factor in the
decreased thermal stability of the fungal enzyme. Previous studies involving the
“GxGxxP” NADH binding motif have shown certain mutations in amino acid residues in
this motif can result in decreased thermal stability and substrate affinities [57].
Interestingly, the C. albicans Cbr1 motif has an alanine substitution (GTGIAP) as
compared to the mammalian threonine (GTGITP), and this may difference in amino acids
in the pyrimidine binding motif may account for the decreased stability and/or NADH
selectivity and catalytic rate. Site-directed mutagenesis of other amino acid residues in
the “GxGxxP” motif may help to provide insight into the distinction of residues involved
in potential altered structure conformational binding and affinity.
Investigation and analysis of the “RxYTSxxSN” motif that is responsible for flavinbinding may also help to explain the similarities in circular dichroism visible spectra
between the mammalian and fungal enzymes.

In C. albicans cb5r the amino acid

sequence is “RSYTPIS,” in comparison to the rat cb5r sequence of “91RPYTPVS97.” Only
two differences in this motif are observed, both occurring at variable positions; otherwise
the amino acid residues are conserved, including Arg91 and Tyr93 which have previously
been implicated in FAD binding [29, 58]. Mutation of Ser92 to Pro resulted in similar
catalytic efficiency and visible CD spectra to that of the wild-type rat cb5r [29], and this
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is the same amino acid substitution present in C. albicans cb5r. In rat cb5r, P92 has been
shown to make several side chain hydrophobic interactions with the flavin isoalloxazine
ring [26]. However, this residue can be substituted to either a proline, serine, or alanine
that is present in other FNR superfamily members that does not affect flavin
incorporation or binding. Due to the high conservation and investigation of amino acid
residue mutations in this signature motif, it can explain why there are little observable
differences in the visible CD spectra between rat and fungal cb5r that account for binding
of the FAD prosthetic group.
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II. PHARMACOLOGICAL CHARACTERIZATION OF C. ALBICANS CB5R USING INHIBITION
STUDIES AND STRUCTURAL ANALYSIS

Due to its important role in ergosterol biosynthesis and P450-mediated detoxification of
xenobiotics, as well as its differences in biochemical properties between that of the
mammalian enzyme, Candida cb5r is a potential fungal drug target. The phylogenetic
analysis of fungal cb5r revealed highest homology to plant homologues (Figure 6);
interesting, plant cb5r is already a herbicidal target, raising the possibility that plant cb5r
inhibitors may represent a new class of antifungals. Hence, I tested several herbicidal
compounds to determine their specific inhibitory activity against C. albicans cb5r.
Compounds included paraquat, rotenone, and acetanilide. Paraquat is a commonly-used
herbicide that is generally non-selective in its mode of action of serving as a generic
electron acceptor [59, 60]. Rotenone is a broad-spectrum pesticide that interferes with
electron transport in the mitochondria by disabling the conversion of NADH to usable
ATP free energy [61]. Acetanilide is an analgesic and antipyretic in the same family as
acetaminophen. Paraquat and acetanilide have previously been determined to cause
acquired methemoglobinemia after exposure to these substances, and therefore have been
proven to have inhibitory actions against cb5r in humans [62, 63]. It was my intent to
determine the activity of these compounds against the fungal cb5r, possibly allowing
insight into new pharmacological agents that are derived from these compounds with less
toxic side effects on the human host. Importantly, all compounds were tested against rat
cb5r as a mammalian control.
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Before testing the inhibitory effects of these compounds on the recombinant
enzyme activity, they were assayed against C. albicans whole cell growth to determine
the IC50, or concentration required to inhibit 50% of cell growth (Figure 17). The
pesticide rotenone had the highest inhibitory effects (IC50 = 17.5 μM), and alachlor
displayed a slightly less inhibitory effect on cell growth (IC50 = 42.9μM). Paraquat had
the least inhibitory effect on C. albicans growth in the millimolar concentration range
(IC50 = 7.0mM) in comparison to the previous micromolar concentrations of the
compounds.

Figure 17. Effect of Herbicidal Inhibitors on C. albicans Cell Growth.
Yeast cells were grown in YPD media with the addition of various
concentrations of selected herbicidal inhibitors. Rotenone had the
highest inhibitory effect (see values below; n=1-2).
Rotenone IC50 = 17.5μM
Alachlor IC50 = 42.9μM
Paraquat IC50 = 7.0mM
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Subsequent inhibition studies using rotenone, alachlor, and paraquat against
recombinant C. albicans cb5r proteins showed little to no effect (data not shown) The
inhibition of C. albicans whole cell growth versus little impact on cb5r enzyme may rely
upon mechanisms outside the specificity of the enzyme. This underscores the necessity to
design more specific compounds that display higher affinity to the fungal enzyme, and
therefore led to NAD+ substrate and nucleotide analogue inhibitory experiments on C.
albicans Cbr1 and Mcr1.
In order to gain insight into potential inhibitors of cb5r, a wide-range of NAD+
substrate analogues and other potential inhibitors have been tested against rat cb5r as well
as both C. albicans Cbr1 and Mcr1 isoforms. By observing which NAD+ analogues affect
catalytic rate, we can better understand substrate binding and gain insight into
pharmacological characterization of the fungal enzyme for further roles in drug discovery
and development.
Nicotinamide adenine dinucleotide (NAD+) is comprised of two nucleotides
connected by their phosphate groups. One nucleotide contains the adenine sugar and the
other nucleotide is nicotinamide (Figure 18). NADH plays an important role as the
electron donor in a wide array of biological processes, including those of the
oxidoreductase family comprised of cb5r and the cytochrome P450 enzymes. Because of
its wide range of distribution in metabolic processes, inhibiting the role of NADH in an
enzymatic reaction is not a valid option as a sole drug target. Therefore, a preliminary
step in drug discovery involves elucidating the specificity of substrate binding as a
beginning step in fragment-based drug design. Observing the inhibitory effect of NAD+
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analogues on enzymatic activity may provide key insight into which structural moieties
(or combinations thereof) of the substrate affect catalytic rate, as well as differences in
the NAD+ ligand binding between rat and fungal enzymes.

Figure 18. The Structure of NAD+

Seventeen NAD substrate analogues as well as the aminocoumarin antibiotic
novobiocin (Figure 19) were investigated as potential inhibitors of cb5r enzymatic
activity, using 100 μM concentration of NAD substrate and 5 mM concentration of
inhibitor. The NAD substrate analogues ADP-Ribose and ADP showed the highest
inhibitory effect on both C. albicans Cbr1 and rat cb5r (Figure 20A, 70% in Cbr1 and
85% in rat, 57% in Cbr1 and 78% in rat, respectively). Following these observations, the
five nucleotide analogues were tested, and it was determined that the purine analogues,
ADP and GDP, showed the highest inhibitory effect against the rat and fungal enzymes
(Figure 20B). Interestingly, GDP showed the highest inhibitory specificity for C.
albicans Cbr1 (48% inhibition) than rat cb5r (19% inhibition). The similarities in
structure between the NADH substrate and the nucleotide purine compound may account
for the highest inhibitory effects in this group.
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Interestingly, S. cerevisiae Cbr1 was first identified as a novobiocin-binding
protein, and it was one of four proteins isolated by novobiocin-agarose chromatography
from yeast lysate [64, 65]. The aminocoumarin antibiotic novobiocin is a potent inhibitor
of bacterial ADP ribosylation by binding to the bacterial DNA gyrase GyrB subunit
involved in energy transduction [66].

Other aminocoumarin antibiotics include

clorobiocin and coumermycin A1 (Figure 19). In yeast, novobiocin causes cell-cycle
arrest in the G1-phase [67]. Therefore, the effects of novobiocin on C. albicans cb5r
activity were assayed, using rat cb5r as a control. Novobiocin showed a higher specificity
for the fungal enzyme as well as the highest inhibitory effects observed, with 79%
inhibition (Figure 20).

Figure 19. The Structure of the Aminocoumarin Antibiotics, Novobiocin,
Clorobiocin, and Coumermycin A1.
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Enzymatic activity was plotted against inhibitor concentration to obtain IC50 values
against C. albicans Cbr1 for ADP-Ribose and novobiocin, the two most effective
compounds against Cbr1 enzymatic activity (Figure 20C). The IC50 of ADP-Ribose was
lower (2.14 mM) than the novobiocin IC50 (3.28 mM).

Figure 20. Inhibitory Effects of Selected Compounds against Rat Cb5r and C.
albicans Cbr1.
(A) Selected NAD substrate analogues were assayed against recombinant C. albicans
Cbr1 and rat cb5r enzymatic activity. Out of the 17 tested, ADP-ribose and ADP had the
greatest inhibitory effect (70% in C. albicans Cbr1 and 85% in rat cb5r, 57% in C.
albicans Cbr1 and 78% in rat cb5r). We also noted that C. albicans Cbr1 showed higher
substrate specificity for NADH than the rat protein for most substrates tested. Novobiocin
was also assayed for inhibitory effects and it was found to have more specific inhibition
on C. albicans Cbr1, with 79% mixed partially non-competitive inhibition (n = 3-6).
(B) Following the observations of the ADP and ADP-ribose showing the highest
inhibitory effect, the five nucleotide analogues were tested as competitive inhibitors. The
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highest inhibitory effect was observed by the purine analogues ADP and GDP. We also
noted that GDP had higher inhibition for the fungal enzyme (48 %) than rat cb5r (19 %).
(C) Enzymatic activity was plotted against inhibitor concentration to obtain IC50 values
against C. albicans Cbr1. The IC50 of ADP-Ribose was lower (2.14 mM) than the
novobiocin IC50 (3.28 mM).
Inhibition constants (Ki values) of the substrate and nucleotide analogues, as well
as novobiocin were also determined against C. albicans Cbr1 enzymatic activity (Figure
21). This was accomplished by creating a double reciprocal plot using three NADH
concentrations (6, 10 and 100μM) that are plotted against the enzymatic rates obtained
using initial-rate enzyme kinetics. By performing regression analysis, one can yield
apparent Km values in the presence of the selected inhibitor from which Ki values are
obtained. If noncompetitive inhibition is present, then the apparent Km is unchanged; in
competitive inhibition, the Vmax is unchanged but the substrate concentrations must be
increased to achieve the catalytic rate in the presence of inhibitor [68].
ADP-ribose exhibited the lowest Ki value (184μM; Figure 21A), followed by the
two purine nucleotides, ADP and GDP (Ki = 231μM; 1.63mM, respectively, Figure 21BC), and the Ki value of novobiocin fell in between the purine nucleotides (747μM, Figure
21D). Due to the intersection of the regression lines along the x-axis, it can be deduced
that ADP-ribose, ADP, and GDP all serve as competitive inhibitors against the NADH
substrate. In contrast, the regression analysis of inhibitory effects of novobiocin against
the C. albicans Cbr1 enzyme displayed a partially non-competitive mixed inhibition,
where the intersection occurs between the x and y-axis coordinates [69].
Although the substrate analogues proved to be a valuable tool in determining the
beginning steps of fragment-based drug design, a Ki value of 100μM or below is desired
before proceeding to the drug discovery stages. Unfortunately, the inhibitors tested did
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not meet this requirement, although ADP-Ribose (Ki = 184μM) had the closest inhibitory
constant.

Figure 21: Ki values of Selected Substrate Analogues and Novobiocin against C.
albicans Cbr1. A double reciprocal plot was created using various NADH concentrations
(6, 10, and 100 μM) plotted against rates obtained using initial-rate enzyme activity.
Concentrations of inhibitor ranged from 0.5-5 mM. Regression analysis (using data
collected in Fig. 20) yielded apparent Km values from which the Ki values were obtained.
(A) ADP-Ribose (184 ± 26 μM).
(B) ADP (231 ± 73 μM).
(C) GDP (1632 ± 382 μM).
(D) Novobiocin (747 ± 51 μM).

LIGPLOT analysis was also performed to compare the structural differences of
rat cb5r and C. albicans Cbr1 proteins at the substrate binding site, using the rat cb5r
crystal structure (PDB 1IB0) as previously described for the FAD LIGPLOT analysis
(Figure 22).
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Figure 22. LIGPLOT Analysis of Cbr1-NAD Interactions. Rat cb5r has 5 hydrogen
bonds and 12 hydrophobic interactions between protein and ligand NAD. In C. albicans
Cbr1, three of these amino acid residues are changed (Gln210-Val; Asp239-Asn; Ala282Met). Interestingly, these substitutions occur closer to the purine moiety of the NAD
ligand, further underscoring the differences in inhibitory effects of the nucleotide
analogues.

The rat cb5r protein has five hydrogen bonds and twelve hydrophobic interactions that
coordinate binding with the NADH ligand. In C. albicans Cbr1, three of these amino
acid residues are changed, including two substitutions of amino acids involved in
hydrogen bonding and one hydrophobic interaction with a substituted residue.
Interestingly, all three of these substitutions are surrounding the adenine moiety of the
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NAD+ ligand. This may account for the purine moiety preference in the fungal enzymes
versus the mammalian counterpart.
In collaboration with Dr. Roman Manetsch of the USF Department of Chemistry,
we began testing compounds synthesized that were based on the substrate analogue
inhibition assays. In the design synthesis, fragment compounds are joined together from
two bases. Providing an assortment of differing combinations of the two starting bases
allows a large number of compounds to be synthesized and subsequently assayed for
inhibitory effects against the fungal enzyme. The two bases utitilized included an amide
moiety that is joined to variations and/or partial moieties of NADH (including
nicotinamide, ribose, adenine, adenosine) . The simplified mechanism used to join the
two bases is shown below.
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Figure 23. Selected Compounds from Fragment-Based Drug Design.
(A) Mechanism used in C. albicans Cbr1 drug design.
(B) The four most effective inhibitory compounds created by the Manetsch
laboratory on C. albicans cb5r enzyme are shown. Various amide
moieties (designated AM) on the right portion of the compound are
joined by the above mechanism to various compounds (TE), some of
which are based on the ribose and/or adenine moiety from the NADH
substrate.

In total, 36 compounds were synthesized and several of these were assayed using the
initial-rate enzyme kinetics assay as previous described.

The four most effective

compounds (Figure 23) were investigated for inhibitory values (Ki). However, when the
potential inhibitors were tested, the Ki values were all above 2.4mM, and therefore these
compounds would have to be refined to improve their inhibitory efficiency (Figure 24).
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Figure 24. Selected Ki Values of Compounds Synthesized as Potential Cbr1
Inhibitors. Compounds synthesized by the Manetsch laboratory that were tested as
potential C. albicans Cbr1 inhibitors included (in order of increasing Ki and thus less
inhibitory effect) TE3NH9, TE2NH9, TE2NH8, and TE2NH2. The nomenclature is
designated by bases used TE(1-3) and NH(1-12), resulting in 36 possible combinations of
compounds using fragment-based drug design (see Figure 23 for above structures).

The seventeen NADH substrate and ADP nucleotide analogues as were also
assayed for their inhibitory effects against the C. albicans Mcr1 protein (Figure 25). In
contrast to the high inhibition rate of ADP-Ribose in the Cbr1 isoform (70% inhibition),
ADP-Ribose only exhibited 10% inhibition against the mitochondrial isoform (Figure
25A). ADP and GDP showed the highest inhibitory effects on the Mcr1 enzyme (45%
inhibition and 30% inhibition, respectively; Figure 25B). C. albicans Mcr1 showed
higher substrate specificity for NADH and less competitive inhibition by substrate
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analogues than the rat cb5r for most substrate analogues tested. In the case of both fungal
cb5r enzymes, GDP proved to be a better competitive inhibitor for C. albicans Mcr1 than
for the rat cb5r, showing that the guanine moiety of GDP appears to bind more tightly in
the substrate binding site of C. albicans cb5r than the mammalian counterpart.

Figure 25: Substrate Specificity of C. albicans Mcr1 and Rat cb5r.
(A) NAD analogues and (B) ADP analogues as competitive inhibitors of enzyme
activity at 100 µM NADH concentration were measured using recombinant C.
albicans or rat enzyme (mean ± S.D.; n = 3-6).
(C) Structure of NADH substrate as compared to purines (ADP, GDP) and
pyrimidines (CDP, TDP, UDP) used in the nucleotide analogue assay.

We performed inhibition assays using NADH substrate analogues as a
preliminary step in development of fragment-based drug discovery against fungal cb5r.
We determined ADP-Ribose and ADP to be the most effective inhibitors of enzymatic
activity, with GDP having more selective inhibition against the fungal protein. By
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observing the structures of these compounds as well as LIGPLOT analysis of the NAD
ligand to protein (Figures 20, 22, 25), it can be deduced that the purine moiety of the
NAD has a major role in interactions between substrate and protein. Moreover, the
guanine moiety of GDP appears to fit better in the substrate binding site of the C.
albicans Cbr1 protein than in the mammalian counterpart (Figure 7B). This can further
be

explained

by

findings

observed

in

an

S127P

mutant

responsible

for

methemoglobinemia in humans [28], in which it was observed that the flavin ADP
moiety made extensive interactions with residues (Y112-K125) located in the protective
lid covering the FAD prosthetic group. This lid is predominantly absent in all fungal cb5r
proteins, denoted by the nine amino acid gap found in sequence alignment analyses,
which may account for these differences in substrate analogue binding between
mammalian and fungal proteins.
Along with differences in NAD binding observed through LIGPLOT analysis, the
structural differences at the substrate binding site between the fungal and mammalian
protein further underscore the potential of C. albicans Cbr1 as a therapeutic target. These
observations may assist in development of selective inhibitory compounds synthesized
through fragment-based drug design.
We also examined the inhibitory effects of the aminocoumarin antibiotic novobiocin
on enzymatic activity of C. albicans Cbr1. Interestingly, yeast Cbr1 was first identified in
a novobiocin-Sepharose binding assay with other S. cerevisiae proteins [70], including
the β-subunit of the mitochondrial F1-ATP synthetase[28]; the myosin heavy chain [3032]; and Sup45, a protein conferring novobiocin-resistance[71].

Novobiocin was

originally identified as an inhibitor of bacterial DNA gyrase as well as eukaryotic type II
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topoisomerases, although after further investigation it was found that novobiocin is not
characterized as a specific inhibitor of these enzymes, but rather may have unspecific
effects from other biochemical targets in yeast and other eukaryotes [34-35].

The

specific effects of novobiocin on yeast Cbr1 were not entirely elucidated, although our
data suggest that the aminocoumarin antibiotic may have a specific inhibitory effect on
cb5r activity, possibly through partially non-competitive mixed inhibition [68].
Discovery of new fungal therapeutic targets is necessary due to the emergence of
drug resistance against the current treatment options. The azole family, including
fluconazole, has been highly effective in combating this invasive fungal pathogen by
targeting the cytochrome P450 enzyme lanosterol demethylase that is responsible for the
formation of lanosterol, an intermediate in ergosterol biosynthesis [14]. However,
resistance to fluconazole and other members of the azole family has become increasingly
prevalent in Candida species [70]. Furthermore, non-albicans species have been reported
to have increased resistance to fluconazole at a higher frequency than C. albicans. This is
particularly disconcerting due to the fact that although Candida is still the most frequent
cause of invasive fungal disease, bloodstream infections involving C. glabrata have
become increasingly prevalent [70]. Therefore, there is an urgent necessity for
development of further therapeutic strategies. Rather than treatment with only one
antifungal agent, combination therapies can assist by targeting a particular entity as well
as deterring the evolution of resistance mechanisms [70]. Cb5r serves as a primary
example as a fungal target to combine in the therapeutic options against fungal disease, as
this protein plays a synergistic role with the cytochrome P450 reductase family in
ergosterol synthesis and detoxification of xenobiotics.
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III. EXAMINATION OF KNOCKOUT PHENOTYPES IN THE YEAST MODEL SYSTEM
SACCHAROMYCES CEREVISIAE

Candida albicans and Saccharomyces cerevisiae have two isoforms of cb5r, ER-specific
CBR1 and mitochondrial outer membrane-specific Mcr1. Gene knockout studies are a
valuable tool to investigate the function of a particular protein and its role in biological
processes within the cell. S. cerevisiae is a prime model for gene knockout studies since
it is a haploid organism, as well as its close phylogenetic relationship to the diploid C.
albicans. In order to characterize their knockout phenotypes, single knockouts of the ERspecific CBR1 (cbr1Δ) and OMM-specific MCR1 (mcr1Δ) have been obtained, and a
double knockout (cbr1Δ/mcr1Δ) devoid of cb5r activity has also been created. The S.
cerevisiae single and double knockout strains were compared to the wild-type parental
yeast strain to investigate their susceptibility to potential environmental stresses such as
temperature and heat shock, acidic pH, oxidative stress, and nutrient availability. The
yeast knockout studies also include challenges of selected antifungal compounds in liquid
cultures as well as a modified version of the Kirby-Bauer disk diffusion assay to assess
the knockout phenotype in the presence of these antifungal drugs. In this second specific
aim (Chapter III) I have tested the hypothesis that susceptibility to environmental
stresses and chemical challenges is increased in the cb5r knockouts.
Wild-type and knockout strains of S. cerevisiae were obtained through the
Saccharomyces Genome Deletion Project (Stanford) and purchased from Open
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Biosystems. In the Genome Deletion Project, single gene knockouts were created using a
PCR-based strategy of replacing the gene of interest with a kanamycin-resistance cassette
for selection (Figure 26). Each of the two mating types (MATa or MATα) can be chosen
for future mating of single knockouts to produce double knockouts for further studies.
The yeast strains also display
differences in auxotrophic
growth between the MAT a
and MAT α strains that can
be utilized in the selection of
double knockouts. Hence, I
obtained knockout strains of
the cb5r ER-specific isoform
CBR1

and

cb5r

mitochondrial-specific
isoform MCR1 together with
the parental wild-type strain
BY4742 as control.
Figure 26. Schematic of Gene Knockout Technique.
PCR-based strategy of replacing the gene of
interest with a selectable marker (G418, Sigma) for selection
(Adapted from SGD Resources).

After obtaining the S. cerevisiae wild-type, cbr1Δ, and mcr1Δ strains, primers
were designed to confirm the gene deletions. Primers were designed to amplify the
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outside sequences flanking the surrounding gene, and thereby amplify either the gene (in
the case of the parental wild-type strain) or the kanMX4 cassette that has been used to
replace the gene of interest. The strains that contain the kanMX4 cassette will display an
amplified region that is approximately 600bp larger than the wild-type genotype (Figure
27).

Figure 27. Confirmation of S. cerevisiae Single Knockout Strains by kanMX4
Cassette.
Primers were designed to target the regions flanking the surrounding gene cassette. In the
WT strain, cbr1 cassette size is 1180bp, and mcr1 cassette size is 1187bp. The cbr1Δ
strain has an increased cassette size of 1795bp due to the presence of the kanMX4
cassette (and thereby deletion of cbr1) but still retains WT mcr1 expression. The mcr1Δ
strain has normal cbr1 expression, and an increased cassette size of 1748bp.

Primers were also designed to target nucleotide sequence motifs that were specific
to either S. cerevisiae CBR1 and MCR1, to exclude the possibility of reintegration of the
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gene elsewhere in the yeast chromosome.This allows confirmation that the
characterizations of the gene knockout phenotypes are valid for the purpose of
subsequent environmental and chemical stressor assays. The primers were designed to
amplify a 270bp size difference between the CBR1 motif sequence (555bp; motif
determined to be specific for each gene) and the MCR1 motif sequence (825bp; Figure
28).

Figure 28. Confirmation of S. cerevisiae Single Knockout Strains by Motif Primer
Design.
Primers were designed to target motifs specific to either cbr1 or mcr1. In the WT strain,
cbr1 motif size is 555, and mcr1 motif size is 825bp. The cbr1Δ strain is negative when
the motif specific to cbr1 is amplified, and the mcr1Δ strain is conversely negative when
mcr1 primers are used.
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The yeast strains containing cb5r single knockouts were first grown in YPD liquid
media at 30°C to observe any differences between the knockout strains in growth rate
under optimal conditions. Yeast strains were first grown overnight to achieve a high
density culture and then diluted to an OD600 between 0.1 and 0.5 to achieve exponential
growth in this early log phase. Cell density was measured by monitoring turbidity every
hour, and doubling times were later calculated. In the control growth rate experiments,
growth of the cbr1Δ and mcr1Δ strains was consistent with that of the wild-type S.
cerevisiae and a linear logarithmic interpretation reveals exponential growth during the
eight hours of observed growth (Figure 29).

Figure 29. S. cerevisiae Wild-type and Knockout Control Growth Curves.
A. Knockout and wild-type strains grown in YPD broth at 30°C. Wild-type S.
cerevisiae had a generation doubling time (Td) = 132 ± 32 min; cbr1Δ Td =
138 ± 18 min; mcr1Δ Td = 139 ± 35 min)
B. Logarithmic scale of data presentation (y-axis) reveals exponential growth
as indicated by a straight line.

The effects of temperature and heat shock on growth and viability of the S. cerevisiae
knockout strains were tested at 25°C and 37°C (heat shock) and compared to 30°C as
control. When the temperature was reduced to 25°C, there was minimal difference in
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growth rates from that of the control growth at 30°C (data not shown). When the yeast
were challenged to heat shock at 37°C, the growth rate of all strains was increased from
the control rate; however, there was little difference observed between the wild-type and
knockout strains (Figure 30).

Figure 30. S. cerevisiae Wild-type and Knockout Growth at 37°C.
Knockout and wild-type strains grown in YPD broth at 37°C as
compared to growth at 30°C. Wild-type S. cerevisiae had a generation
doubling time (Td) = 96 ± 26 min; cbr1Δ Td = 99 ± 24 min; mcr1Δ Td =
94 ± 31 min (n = 3).

The effects of nutrient availability were observed by first comparing growth of
cultures in YPD broth to minimal SD broth. While YPD broth is a rich medium that
contains a blend of peptones, yeast extract, and dextrose optimum for growth, minimal
SD broth contains only a nitrogen base, ammonium sulfate, and dextrose. The
environmental stress of starvation conditions were also mimicked by using 10% minimal
SD broth. Due to role of cb5r in ergosterol biosynthesis and fatty-acid elongation, it was
hypothesized that the reduced nutrient conditions may impact the knockout strains more
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than wild-type yeast growth, as the yeast do not have nutrients readily available as in
YPD media. Although reduced growth rate was observed in minimal SD and 10%
minimal SD broth, and growth rate was slightly increased during heat shock at 37°C,
there was little difference in growth of the cbr1Δ and mcr1Δ strains from the wild-type S.
cerevisiae (Figure 31). When the S. cerevisiae strains were grown in SD and 10% SD
medium, the growth rate observed is extremely slow to previously published growth
rates. This may be due to an unknown auxotrophic marker in these specific strains that
required additional amino acids, sugars, etc.; however, the trends between the individual
wild-type and knockout strains are still evident.

Figure 31. S. cerevisiae Wild-type
and Knockout Growth in Reduced
Nutrient
Availability
and
Starvation Conditions.
(TOP) Knockout and wild-type
strains grown in 10% SD broth at
30°C. Wild-type S. cerevisiae had a
generation doubling time (Td) = 1806
± 325 min; cbr1Δ Td = 1688 ± 589
min; mcr1Δ Td = 1719 ± 507 min).
(BOTTOM) Knockout and wildtype strains grown in 10% SD broth
at 37°C. Wild-type S. cerevisiae had
a generation doubling time (Td) =
1554 ± 662 min; cbr1Δ Td = 1506 ±
248 min; mcr1Δ Td = 1527 ± 693
min (n = 3).
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The effects of acidic pH (pH 5.5) were also investigated and compared to neutral
pH 7. The acidic pH was chosen to mimic conditions in the human host in which C.
albicans is phagocytosed by macrophages and polymorphonuclear neutrophils (PMNs)
with an acidic lysosomal pH of approximately 5.5, and 10% SD broth was used as a
minimal medium with little buffering capacity. Although the mcr1Δ strain displayed a
slightly decreased growth rate compared to wild-type S. cerevisiae (1841 min, 1598 min,
respectively), the cbr1Δ strain displayed a significantly decreased growth of only 70% of
the growth rate of wild-type (2287 min; Figure 32). Interestingly, several proteins that
may potentially interact with Cbr1 (see Chapter IV) are induced under conditions of weak
acid stress, such as alcohol dehydrogenase II (ADH2) and D-xylose reducatse (GRE3).
This illustrates the greatest impact seen on the cbr1Δ strain, which is suggestive of a role
in a virulence mechanism that is induced under conditions of weak acid stress.

Figure 32. S.
cerevisiae Wild-type
and Knockout
Growth under
Acidic Stress.
Acidic
conditions
(pH
5.5)
were
created using 25mM
MES
to
10%
minimal SD media.
Wild-type
S.
cerevisiae exhibited
a generation time of
1598 ± 507 min, mcr1Δ Td = 1841 ± 396 min, and cbr1Δ had a significantly
increased Td = 2278 ± 885 min (n = 3).
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The potential effect of oxidative stress on the knockout strains was investigated by
the addition of various concentrations of hydrogen peroxide (H2O2) to the growth
medium. In the phagolysosome of macrophages and PMNs, C. albicans faces oxidative
stress due to reactive oxygen species (ROS) released by these cells upon oxidative
metabolic burst. C. albicans has a greater natural resistance (10-50 mM) to H2O2 than S.
cerevisiae (1-5 mM), and therefore concentrations were adjusted to reflect the oxidative
stress tolerance constraints of S. cerevisiae [72-75]. After inoculation of a high density
culture to create a cell density starting growth rate indicative of exponential phase, the
yeast cells were allowed to recover for thirty minutes before being challenged with either
0.5 mM or 2.0 mM H2O2 and subsequent cell densities monitored every hour. When
challenged with 2.0 mM H2O2, the cell density of the yeast cultures did not increase over
the time period observed, but rather remained stationary; therefore, 0.5mM H2O2
conditions were used as a concentration that creates oxidative stress without cell death.
Wild-type and cbr1Δ strains were similar in growth rate with that of the ER-specific
knockout having a slightly increased doubling time (Wild-type Td = 638 ± 123 min and
cbr1Δ Td = 700 ± 118 min; Figure 33). However, the mcr1Δ strain exhibited a decreased
growth rate over 40% slower than wild-type S. cerevisiae growth (Td = 1075 ± 158 min).
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Figure 33. S. cerevisiae Wild-type and Knockout Growth under Oxidative
Stress
Conditions of oxidative stress were created by adding 0.5mM H2O2 to 10%
minimal SD medium. Wild-type S. cerevisiae exhibited a generation time of 638
± 123 min, cbr1Δ Td = 700 ± 118 min, and mcr1Δ had a significantly increased
Td = 1075 ± 158 min (n = 3).

Recent evidence reveals that C. albicans Mcr1 is induced under oxidative stress,
and another publication reports an overexpressing-Mcr1 mutant in S. cerevisiae which
exhibited increased resistance to oxidative stress [72, 74, 76]. A potential protein
interaction of C. albicans Cbr1 is the AMP-activated protein kinase, KIS1, a regulator of
sugar metabolism; null KIS1 mutants display hypersensitivity to oxidative stress [72].
Although the protein interactions were performed with C. albicans Cbr1 isoform, the
Mcr1 isoform may interact with similar proteins as KIS1 as it appears to play a more
significant role in the oxidative stress response.
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Although the above results do imply some disparity between wild-type S.
cerevisiae growth versus that of the cbr1Δ and mcr1Δ, such as under conditions of acidic
and oxidative stress, an investigation into a cbr1Δ/mcr1Δ strain devoid of cb5r activity
was a practical next step in the yeast gene knockout studies. To accomplish this, the S.
cerevisiae single knockout strains, cbr1Δ (MATα:: his3∆1:leu2∆0:lys2∆0:ura3∆0) and
mcr1Δ (MATa:: his3∆1:leu2∆0:met15∆0:ura3∆0), were mated on YEPD plates
containing the kanMX4 resistance marker, G418 [48]. Diploid selection was performed
on -met / -lys dropout agar plates, since these are the auxotrophic markers that are each
unique to their mating type.

Following sporulation, tetrad growth was assessed to

observe a phenotype indicative of a cbr1Δ/mcr1Δ strain. In this mating cross, statistically
a tetrad having a 2:2 ratio on G418-containing agar would be positive for two double
knockout clones, as the single knockout mating cross yielded two double knockout
genotypes and two wild type genotypes of the wild-type S. cerevisiae BY4742 parental
strain (lacking the kanMX4 resistance cassette and does not grow on G418-containing
agar). From a antifungal therapeutic perspective, a double knockout of CBR1 and MCR1
that is synthetically lethal is preferred, as this indicates the vital role of cb5r in the yeast
cell; however, if the double knockout is not synthetically lethal, the ratio serves as a
genetic analysis tool to select the desired yeast genotypes to be assayed. Statistically, a
3:1 ratio would have all four possible strain combinations of wild-type, cbr1Δ, mcr1Δ,
and cbr1Δ/mcr1Δ; a 4:0 ratio has yielded single knockouts identical to the cbr1Δ and
mcr1Δ strains used in the mating cross. Fifteen tetrads were assessed, with two tetrads
having the 2:2 ratio (Figure 34). These results already provide evidence that a double
knockout of S. cerevisiae cb5r is not synthetically lethal, and this may be explained by
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the difference compartmentalization in the cell (Cbr1:ER; Mcr1:OMM), although this
does decrease the potential as a novel antifungal target. These four clones from the 2:2
ratio tetrads, as well as three other clones from a 3:1 ratio tetrad, were selected for
screening by PCR analysis to denote the presence of the kanMX4 cassette indicative of
the gene knockout.

Figure 34. S. cerevisiae Tetrad Growth Following Mating of cbr1Δ and
mcr1Δ Strains.
A. When tetrads isolated following sporulation are grown on YEPD agar
lacking the G418 selection marker, all four clones of the fifteen tetrads can
grow.
B. When the original plate is replica-plated onto YEPD agar containing G418,
individual clones of the tetrads can be assessed for presence of the kanMX4
cassette indicative of gene deletion. Two tetrads (position 3 and 12) revealed a
2:2 ratio which implies two double knockouts (cbr1Δ/mcr1Δ) have grown and
the two absent clones have the parental genotype reestablished.

The seven clones chosen to screen as possible double knockouts were analyzed by
PCR (as previously performed with the single knockouts). In the initial screening of all
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seven possible clones, cassette primers designed to amplify the flanking region
surrounding the gene of interest were used to observe the increased band size indicating
the presence of the kanMX4 cassette.

Out of the seven clones, four clones were

confirmed as double knockouts (Figure 35).

Figure 35. Confirmation of S. cerevisiae Double Knockout Strains by kanMX4
Cassette.
Primers designed to target the regions flanking the surrounding gene cassette and amplify
the kanMX4 cassette in the absence of the gene of interest. Out of the seven possible
clones obtained from tetrad selection, four clones were found to be positive as S.
cerevisiae cbr1Δ/mcr1Δ double knockout strains.
Growth of all four cbr1Δ/mcr1Δ double knockouts was assessed to determine if
there was any variation of growth rate among the four clones. When grown in YPD
media at 30°C, the four clones exhibited growth rate consistent with that of wild-type S.
cerevisiae as well as the single knockouts. S. cerevisiae cbr1Δ/mcr1Δ clone 2 was
chosen, although the other double knockout clones were frozen if further experiments
warranted.
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All four strains used in the subsequent yeast knockout studies are shown in
Figures 36 and 37. The first denotes use of the cassette primers used to amplify the
kanMX4 cassette and the latter represents the presence of isoform-specific motif.

Figure 36. Confirmation of All S. cerevisiae Knockout Strains by kanMX4 Cassette.
Primers designed flanking the kanMX4 cassette were used to denote the knockout of the
cb5r genes in S. cerevisiae (single and double knockouts, respectively). When the gene is
not present, the band size increases with the insertion of the kanMX4 cassette; otherwise
the smaller band sizes denotes presence of cb5r protein.
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Figure 37. Confirmation of All S. cerevisiae Double Knockout Strains by Motif.
Primers were designed for gene sequences specific to either the CBR1 or MCR1
isoform in order to confirm the knockout of either or both genes.

After confirming the cb5r double knockout, experimental assays were developed
to determine if the proteins play a role in response to selected antifungal therapeutics.
The yeast knockout strains were challenged with the following compounds: amphotericin
B (AmB), disruptor of cell membrane; ketoconazole (KTZ), inhibitor of ergosterol
biosynthesis in the yeast cell membrane belonging to the azole family; 5-fluorocytosine
(5FC), an inhibitor of nucleic acid synthesis; griseofulvin (Gris), an inhibitor of
microtubule assembly; and farnesol, a quorum sensing molecule involved in biofilm
formation. AmB and KTZ were selected because of their mode of action that targets
ergosterol in the cell membrane, as fungal cb5r plays a role in ergosterol biosynthesis.
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Farnesol was selected due to a recent report that C. albicans MCR1 is upregulated
in high farnesol concentrations [8]. The other compounds were chosen as negative
controls with targeted mechanisms outside of the role of cb5r in the cell membrane.
In preliminary experiments performed in liquid YPD medium, the concentrations
of the selected compounds was based on previous IC50 and MICs reported in the literature
[8, 14, 19, 21, 70, 76-78]. As in previous experiments, a high density overnight culture
was used to inoculate a fresh culture with a cell density in log-phase exponential growth.
The antifungal compounds were resuspended in DMSO, and therefore 1% DMSO was
added to a control growth culture to account for any impact of the organic solvent on
yeast cell growth. Although a slight increase in doubling times among the cbr1Δ/mcr1Δ
strain was seen in cultures containing KTZ, the most dramatic results of decreased
growth rate occurred when the double knockout was challenged with AmB (Figure 38).

79

Figure 38. S. cerevisiae Wild-type and Knockout Growth in the Presence
of Selected Compounds.
Concentrations of the selected compounds are shown under the graph. 1%
DMSO was added to a control culture (n=3-4).
The double cbr1Δ/mcr1Δ knockout strain showed a decreased growth rate in
the presence of AmB and KTZ. Little differences were seen among the 5FC
samples, as was expected due to its mode of action outside the role of cb5r.

Due to the high standard deviation of growth rate in liquid culture, a method
involving solid YEPD agar and a modified version of the Kirby-Bauer disk diffusion
assay. In this assay, 300,000 yeast cells from a high density overnight culture are added
to 0.7% YEPD top agar, vortexed thoroughly, and homogenously added to sterile YEPD
agar plates. Once the plates have dried, Whatman filter disks containing serial dilutions
of the selected antifungal compound are added sterilely to the agar plates with tweezers.
Whatman filter disks containing 1% DMSO are used as a control. The plates are then
80

incubated 16-20 hours at 30 °C, and zones of inhibitions around each filter disk are
observed.
No observable differences were seen when the yeast knockout strains were
challenged with griseofulvin or farnesol (data not shown), and little to no difference in
the presence of 5FC (Figure 39). However, the most surprising results were seen when
the single and double knockout strains were challenged with AmB and KTZ. The single
knockouts showed increased resistance to AmB, and the cbr1Δ/mcr1Δ strain exhibited
almost complete resistance against AmB (Figure 39).

Since cb5r plays a role in

ergosterol biosynthesis, the knockout strains have developed resistance due to a lack of
the drug target of AmB, ergosterol, in the fungal cell membrane. Although ergosterol is
usually the predominant sterol found in fungal cell membranes, there are a variety of
other sterols that comprise the sterol composition of the membrane. These sterols result
from deviations from the dominant ergosterol biosynthetic pathway to alternative
pathways utilizing the intermediate compound, lanosterol.
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Figure 39. S. cerevisiae Wild-type and Knockout Growth in the Presence
of Selected Compounds.
AmB concentrations used: 250, 125, 50μM; KTZ concentrations used: 1, 0.5,
0.2mM; 5FC concentrations used: 25, 12.5, and 6.75 mM; 1% DMSO is
added to Whatman filter disks as control.
The single and double cbr1Δ/mcr1Δ knockout strains showed increased
resistance to AmB and KTZ. Little differences were seen among the 5FC
samples, as was expected due to its mode of action outside the role of cb5r.
Another interesting and unexpected observation is the increased resistance to KTZ
and AmB that occurs in the single and double knockouts. There are several mechanisms
of resistance to azoles, the two most documented of which are mutations in the target
enzyme CYP51 (Erg11 protein) and multi-drug resistance transporters responsible for
efflux of the antifungal drugs. A third mechanism of azole resistance involves mutations
in the sterol C5-desaturase, Erg3, an enzyme that participates in one of the last reactions
of ergosterol biosynthesis downstream of lanosterol. Erg3 also catalyzes the formation of
14-methylated ergosta-diol toxic intermediates, an alternative sterol pathway that is
upregulated upon Erg11 inactivity and ergosterol depletion following azole treatment
(Figure 40). However, it is not the lack of ergosterol in the cell membrane that is
responsible for cell death, but rather the build-up of these toxic ergosta-diol
intermediates. When Erg3 is inactivated, it can suppress toxicity by lack of the ergosta-
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diol intermediates, and therefore lead to azole resistance. It has been documented that
Erg3 deletions in both S. cerevisiae and C. albicans conferred high levels of azole
resistance, and more recently sterol C22-desaturase (Erg5) deletions as well [14, 15, 18,
21, 70, 76]. Erg5 contributes to the penultimate step of ergosterol biosynthesis following
Erg3, and also plays a role in the conversion of 14-methylated toxic intermediates.
Interestingly, these are the two cytochrome P450 reductases that cb5r has known
interactions of electron transfer. Therefore, it is hypothesized that cb5r may play a more
vital role in electron transfer to the cytochrome P450 family, and the function of Erg3 and
Erg5 requires involvement of the reducing equivalents of cb5r and cb5.
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Figure 40. Diagram of the ergosterol biosynthetic pathway and
alternative sterol metabolism in C. albicans.
(A) Accumulation of ergosta 5,7-dienol with perturbation of Erg5 function
but without azole inhibition of Erg11.
(B) Sterol intermediates that accumulate with classical azole inhibition of
Erp11. The end products are the toxic 14-methyl ergosta-diol
intermediates.
Open arrow: Erg5; broken arrows: multiple enzymatic steps; solid arrows:
single enzymatic step. [16]

To further elucidate the function of cb5r in azole and AmB resistance, an assay
was designed to supplement the growth media with ergosterol (Figure 41). If ergosterol
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is present for the yeast to utilize in their cell membrane, its presence in the media should
also restore sensitivity to AmB. The effects of KTZ resistance upon adding ergosterol to
the growth medium are less evident, although it was speculated that even though
ergosterol is available to be utilized as the dominant sterol, the cb5r knockout strains may
still lack the ability of the conversion of the 14-methylated toxic intermediates and thus
retain azole resistance.

Figure 41. S. cerevisiae Wild-type and Knockout Growth in the Presence
of AmB and KTZ with Ergosterol Supplementation in the Growth Media.
AmB concentrations used: 250, 125, 50μM; KTZ concentrations used: 1, 0.5,
0.2mM; 5FC concentrations used: 25, 12.5, and 6.75 mM; 1% DMSO is
added to Whatman filter disks as control. 50mM ergosterol is added to the
0.7% YEPD top agar.
AmB sensitivity is not restored upon addition of ergosterol to the growh
media. Little visible differences are also observed in the KTZ samples.

Upon addition of ergosterol to the yeast growth media, AmB sensitivity was not
restored, as was hypothesized. There were little observable differences between the wildtype and knockout strains of the KTZ samples plus ergosterol, although adding ergosterol
85

did increase resistance of the wild-type and single knockout strains as compared to agar
depleted of ergosterol. This can be explained by the presence of Erg11, the target of the
azole family, in all of the yeast strains used in these experiments [21].
In order to elucidate possible alternate sterol production of the S. cerevisiae
knockout strains, membrane sterols were extracted and analyzed using the methodology
of Arthington-Skaggs et. al. [54]. This method utilizes the unique spectral absorbance
patterns of ergosterol and DHE (ergosta-5,7,24(28)-trienol), a late sterol pathway
intermediate. In the UV absorbance spectrum between 230 and 320 nm, ergosterol
displays four characteristic peaks indicative of its conjugated double bond system,
whereas DHE displays a single spectral peak at 230nm. Ergosterol and DHE display an
absorbance spectra at 281.5nm whereas only DHE is present at 230nm. The ergosterol
content is calculated as a percentage of the net wet weight of the cell by the following
equations:
% Ergosterol + DHE = [(A281.5nm/290) x F] / pellet weight
% DHE = [(A230nm/518) x F] / pellet weight
% Ergosterol = (% Ergosterol + DHE) - % DHE
where F is the dilution factor in heptane, and 290 and 518 are the E values (in percent per
centimeter) determined for crystalline ergosterol and DHE, respectively [54].
The sterols of wild-type S. cerevisiae and several erg mutants were first isolated
to validate the method and ensure its reproducibility (Figure 42).

Wild-type yeast

displayed the characteristic four-peaked absorbance spectra of ergosterol, whereas erg3∆
has only one peak of spectral intensity at 230nm indicative of DHE; erg6∆ contains both
the four-peaked spectrum, as well as an absorption peak at 230nm [22]. The erg5∆ strain
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has not been previously investigated, but it was found to behave similarly to wild-type S.
cerevisiae, as expected.

Figure 42. UV Absorption Spectra of S. cerevisiae Wild-type and Selected
erg Mutants, erg3∆, erg5∆, and erg6∆.
Wild-type ergosterol displays a four-peak absorption spectra, whereas the
erg3∆ mutant displays a single peak at 230nm, indicative of DHE as the
dominant sterol. The erg6∆ mutant displays the characteristic four-peak
absorption spectra in addition to a peak at 230nm. The erg5∆ mutant appears
to have a sterol composition similar to wild-type S. cerevisiae.

The sterols of the cb5r single and double knockouts were isolated and analyzed
using the Arthington-Skaggs methodology, and all three were found to display UV
absorbance spectra and ergosterol content similar to wild-type S. cerevisiae (Figure 43;
Table 5). The S. cerevisiae cb5r knockout strains were then challenged with various
concentrations of ketoconazole, ranging from 2µM - 100µM, and extracted sterols were
analyzed by their UV spectrophotometric profiles (Figure 43).
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Figure 43. UV Absorption Spectra of S. cerevisiae Wild-type and cb5r
Knockouts in the Presence of 2µM Ketoconazole.
The presence of KTZ decreases the concentration of ergosterol in all strains,
with the exception of the cbr1∆/mcr1∆ mutant strain that displays a similar
absorption spectra to the erg6∆ strain.

At concentrations above 10µM, all sterol profiles appear as a flattened line, and therefore
only 2-10µM concentrations were considered significant. A decrease in percent
ergosterol content is evident as ketoconazole concentrations are increased, although no
significant differences are seen between wild-type S. cerevisiae and the cb5r knockouts
(Figure 43). Levels of ergosterol content appear to drop more steadily than the knockouts
ergosterol content, although susceptibilities to ketoconazole eventually level out after the
5µM concentration. The double knockout appears to display a higher absorance at
230nm than the rest of the samples when challenged with ketoconazole, and suggests
increased levels of DHE, the late sterol intermediate, and this is confirmed when the data
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are quantitated (Table 5), the double knockout contains the highest levels of DHE
content per cell as compared to the wild-type and single knockout sterol composition
profiles.
Table 5. Mean Ergosterol and DHE Contenta of S. cerevisiae cb5r Knockout Strains

S. cerevisiae strain

Ergosterol

DHE

BY4742 (WT)
cbr1∆
mcr1∆
cbr1∆/mcr1∆

2.22 ± 0.03
2.36 ± 0.33
1.97 ± 0.54
2.19 ± 0.39

0.29 ± 0.10
0.31 ± 0.18
0.33 ± 0.07
0.40 ± 0.09

a

Expressed as a percentage of the wet weight of the cell ± the standard error of the mean using the
following equations: % Ergosterol + DHE = [(A281.5nm/290) x F] / pellet weight; % DHE = [(A230nm/518) x
F] / pellet weight; % Ergosterol = (% Ergosterol + DHE) - % DHE; where F is the dilution factor in
heptane, and 290 and 518 are the E values (in percent per centimeter) determined for crystalline ergosterol
and DHE, respectively [54].

Figure 44. Decrease in Ergosterol Content with Increasing Ketoconazole
Concentrations. Using the Arlington-Skaggs sterol quantitation method as
previously described, ergosterol content was determined in the presence of 0,
2, 5, and 10µM ketoconazole. Specific values of % ergosterol are indicated in
Table 5.
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Fungal cb5r plays an important role in ergosterol biosynthesis and cytochrome
P450-mediated detoxification of xenobiotics, although little has been documented about
gene knockout studies involving cb5r. The use of single knockout studies in the presence
of certain environmental stresses delivered insight into the role of Mcr1 in the oxidative
stress response, as well as Cbr1 and other proteins induced under conditions of weak acid
stress.
The double knockout studies null of cb5r activity demonstrated AmB resistance,
thereby underscoring the important role of cb5r in ergosterol biosynthesis. When
ergosterol was supplemented in the growth media, sensitivity was not restored, as
previously expected. Although ergosterol is present in the media, the single and double
knockouts may have already undertaken alternative pathways of sterol synthesis, and the
excess ergosterol in the media may not have been incorporated. This would explain how
AmB resistance is still evident among the yeast strains lacking cb5r. The aerobic sterol
exclusion molecular mechanism further supports this finding, in which S. cerevisiae does
not take up exogenous sterols in aerobic conditions but rather synthesizes the membrane
sterols [79, 80]. Therefore the yeast synthesizes sterol compounds based upon the critical
step in the ergosterol biosynthetic pathway from which mutations or deletions occur.
Barker et. al. elucidated the enzymes encoding these critical steps in which alternate
sterol production occurs as Erg5, Erg6, and Erg25 [19]. Interestingly, cb5r has been
previously demonstrated to have a role in electron transfer to Erg5, the CYP450 sterol
desaturase which catalyzes the penultimate step in ergosterol biosynthesis as well as
alternate sterol production in the presence of azoles [36, 81].
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The results also implicate the role of cb5r in azole resistance, as seen through the
single and double knockouts increasing resistance to KTZ. This can be explained by the
role of Cbr1 and Mcr1 in electron transfer to Erg3 and Erg5, cytochrome P450 reductases
that are involved in the conversion of 14-methylated ergosta-diol toxic intermediates, the
alternative pathway utilized when azoles inhibit the function of lanosterol demethylase,
Erg11 (Figure 40). When cb5r is not present for this electron transfer to Erg3 and Erg5,
tolerated ergosta-diol intermediates are accumulated that suppress the yeast cell’s toxicity
to the azole treatment [14, 15, 19, 76]. These findings are further supported by microarray
studies involving genes upregulated in the ergosterol biosynthetic pathway during
ketoconazole exposure, in which C. albicans cb5 and Mcr1 were identified [70, 76].
Interestingly, recent findings that utilized a protein pull-down assay to identify
interactors of S. cerevisiae Ste20, a regulator of mating, filamentous growth, and the
osmotic stress response, has found the Cbr1 isoform to have a role in regulation of cell
polarity during filamentous growth with Ste20 [82]. Three proteins involved in sterol
biosynthesis, Ncp1 and Erg4 in addition to Cbr1, have putative function in electron
transfer to Ste20, although the exact mechanism has not been elucidated. Ncp1 (SGD ID:
YHR042W; alias CPR1) is a member of the CYP family, and appears to have overlapping
functions with Cbr1 in sterol synthesis [82], although NADPH is the preferred electron
donor in contrast to NADH with Cbr1. In knockout studies, single knockouts of either
Ncp1 or Cbr1 proved to be viable, albeit have a decreased growth rate, as the above
results verify for single knockouts of either cb5r isoform. However, a cbr1∆/ncp1∆
mutant is inviable and therefore the investigators created a conditional lethal strain that
utilized a temperature-sensitive degron that caused the mutant strain to grow at room
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temperature, but not at temperatures above 37 ºC. Their results indicate a morphological
defective strain that shows aberrant bud morphology in the cbr1∆/ncp1∆ strain. This
overlapping function of Cbr1 and Ncp1 may help to explain the preceeding results for
viability of the cbr1∆/mcr1∆ strain, in that Ncp1 can transfer electrons to members of the
CYP family in the absence of the cb5r proteins. Although a double knockout of Cbr1 and
Mcr1 cb5r isoforms is not synthetically lethal, they also appear not to be functionally
redundant, probably due to the differences in compartmentalization in the cell. Also, the
cb5r knockouts did not display significant differences in the sterol analysis by UV
spectral absorption, and this may be further explained by the redundant functions of Cbr1
and Ncp1. In order to confirm this hypothesis, a mutant lacking Cbr1, Mcr1, and Ncp1
would have to be created and examined for phenotypic and/or morphological changes.
The role of cb5r in S. cerevisiae and the closely-related C. albicans has not been
completely elucidated, but these results confirm the importance of cb5r in ergosterol
biosynthesis through its electron transfer to the cytochrome P450 family. It is also the
first documentation of the involvement of both S. cerevisiae cb5r isoforms cbr1 and mcr1
in AmB and KTZ resistance. One point to mention is that resistance caused by mutations
or deletions in the haploid S. cerevisiae may not be completely indicative of the cellular
response in the diploid C. albicans, and therefore gene knockout studies may differ
between the two fungi.

However, by understanding resistance mechanisms and the

enzymes that are responsible, the next generation of antifungal drugs can be designed to
better defy the fungal resistance mechanisms and improve antifungal treatment options.
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IV. A PRELIMINARY INVESTIGATION INTO THE PROTEIN:PROTEIN INTERACTIONS
OF C. ALBICANS CBR1 AND CYTOPLASMIC PROTEINS

Cb5r is involved in numerous biological processes where cb5 acts as the standard
physiological electron acceptor. However, there is evidence that cb5r may interact with
proteins other than cytochrome b5, such as members of the cytochrome P450 family
involved in drug detoxification. Furthermore, cb5r participates in a diverse array of
biological processes in different subcellular locations, such as the ER and mitochondria.
In order to elucidate potential interactions of cb5r with other cytoplasmic proteins, protein
pull-down assays or co-immunoprecipitation will be discussed. In this specific aim, the
hypothesis that cb5r interacts with other cellular proteins in addition to cb 5 was
examined, and may provide valuable insight into the identification of novel drug targets
related to cb5r and drug resistance.
A histidine-tag protein purification pull-down assay was utilized to identify
protein interactions between C. albicans cb5r Cbr1 and other cytoplasmic proteins. In this
method, C. albicans cell lysate is incubated with the His6-tagged Cbr1 that serves as the
“bait” for other proteins. Cytoplasmic conditions are mimicked by creating an osmolarity
of 120 mM NaCl and 50 mM DTT to simulate the reducing cytoplasmic environment. In
order to capture potentially weaker interactions, additional cross-linking can be utilized,
using a bifunctional medium-length (11Å) cross-linker for cross-linking between two
amino groups (DMS, dimethyl suberimidate-HCl; Pierce). In this assay, C. albicans cell
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lysate is incubated with the His6-tagged Cbr1 as bait to allow binding of the His6-tagged
Cbr1 with other proteins in the C. albicans cell lysate. The His6-tagged Cbr1 and its
interacting proteins are co-purified by affinity ligand capture using Ni-NTA column
chromatography. Following the protein pull-down assay, the resulting protein samples
are subjected to SDS-PAGE analysis. As a negative control for nonspecific binding,
pull-down assays are performed without the His6-tagged Cbr1 as bait. Bands specific to
the pull-down assays are excised from the SDS-PAGE gel and subjected to tryptic digest.
Finally, mass spectrometric analysis using tandem MALDI-TOF/TOF spectrometry was
used to identify and sequence the resulting peptide fragments of proteins that interact
with C. albicans Cbr1.
As an alternative technique to determine protein interactions, coimmunoprecipitation (co-IP) can be used. For this method, high-affinity peptidespecific antibodies were produced (polyclonal rabbit serum) that target the C-terminal
region unique for the two C. albicans cb5r isoforms (10-aa peptide in Cbr1, 13-aa
peptide in MCR1; Table 6). The benefit of this method is that proteins can be crosslinked within intact C. albicans cells prior to cell lysis and the following co-IP assay.
In contrast to the above histidine-tagged protein pull-down assay which uses total cell
lysate, the co-IP assay has the advantage to only cross-link proteins that are localized
naturally within the same subcellular compartment of the intact cell. In order to
accomplish this, C. albicans spheroplasts (i.e. intact yeast cells lacking the cell wall)
are produced by enzymatic digest of the cell wall [71]. Subsequently, the membranepermeable DMS cross-linker is utilized to cross-link potentially weaker protein
interactions or membrane-bound proteins that are more difficult to isolate due to their
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hydrophobicity. Following cross-linking of intact spheroplasts, yeast cells are lysed
and incubated with the anti-cb5r antibody (anti-Cbr1 or anti-Mcr1). Additionally, the
isoform-specific antibodies against cb5r also allow for confirmation of the purified
proteins by Western blot analysis.

Table 6. Peptide-specific antibodies against the C-terminal region unique
for the two C. albicans cb5r isoforms (ER-specific Cbr1 and mitochondrialspecific Mcr1).
CaCbr1 C-terminus:
NLLCGPPPMVSAMKKAAVELGFQKAKPVSKLGDQVFVF*
P

+LGF+K

+ VF F

CaMcr1 C-terminus:
SGPKVSPTDQGELTGALKDLGFEK--------EHVFKF*

Unfortunately the isoform-specific cb5r antibodies did not yield any apparent
results of protein interactions, possibly due to the low purity of the antibodies obtained
from the polyclonal rabbit serum. In order to increase the efficacy of the antibodies, they
would need additional purification steps before use in the protein-protein interactions
assay.

However, the protein pull-down assay using recombinant C. albicans Cbr1

histidine-tagged protein yielded reliable and repeatable results when performed several
times with Cbr1 protein purified from different large-scale preparations, as well as
creating spheroplasts to identify protein-protein interactions within the same subcellular
compartment.
In the preliminary steps of the pull-down assay, cobalt resin was used as the
affinity ligand capture method to purify the protein-protein interaction complexes. Using
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this method, we were able to observe two major and two minor bands in Coomassiestained denaturing gels (Figure 45). The two major bands appear to correspond to the
Cbr1 bait protein and its electron acceptor cb5 (28.7 kDa and 12.1 kDa, respectively).
Use of the DMS crosslinker revealed a potential interacting protein at ~18.5 kDa and a
potential multi-protein complex at ~63 kDa that may be comprised of Cbr1, cb5, and
other interacting proteins.

Figure 45. Protein:Protein Interactions of C. albicans Cbr1 and C. albicans Cell
Lysate using the Pierce Pull-Down Assay Kit.
Coomassie-stained SDS-PAGE gel using C.albicans His6-tagged Cbr1 (28.7 kDa) as
bait revealed protein-protein interactions with cb5 (12.1 kDa) as well as potential
interaction with an unknown protein ~18.5 kDa in size. DMS cross-linking furthermore
revealed an apparent protein complex of ~ 63 kDa that may comprise Cbr1, cb5, and
additional interacting proteins.
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In order to increase the concentration of the purified co-interacting proteins, the
pull-down assay was modified to use the Ni-NTA resin used in large-scale purification of
the recombinant protein. The rationale would be the histidine-tagged protein would have
higher affinity to the Ni-NTA resin used in purification rather than the cobalt chelate
resin utilized in the Pierce kit. When the purification efficiency is compared, it is
obvious that higher yields of co-interacting proteins are found using the Ni-NTA resin,
used in combination with the DMS crosslinker (Figure 46).

Figure 46. Comparison of CoPurified Proteins between Ni-NTA
and Cobalt Resin.
Results of the Cbr1 protein pull-down
assay. Lane 1 is Cbr1 “bait” protein
only and Lane 2 is C. albicans cell
lysate only as negative control. The
samples in Lanes 3 and 4 were copurified using cobalt resin, versus NiNTA purification (lane 5).

Using the optimized protein pull-down assay methodology, six dominant bands are
revealed between a low molecular weight range of ~12 kDa to almost 60 kDa (Figure
46). The most dominant band (Figure 47, designated below as Protein 3) is hypothesized
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to be C. albicans Cbr1, with a molecular weight of 28.7 kDa. However, to confirm the
identity of these proteins, the six dominant bands were excised from the protein gel
(Figure 47) and analyzed by MALDI-TOF/TOF mass spectrometry at the IDRB
Proteomics facility (Tampa, Florida). Since there are limited publications concerning cb5r
protein-protein interactions, MALDI-TOF/TOF was chosen due to its large mass range
and sensitive detection methods [83].

Figure 47. Bands Excised for
Identification by MALDI-TOF
Analysis.
Six dominant bands (Proteins 16) were excised and subsequently
examined
by
mass
spectrophotometric analysis.

Upon mass spectrophotometric analysis, 29 total spectra were obtained and
visualized using the Scaffold proteome software, and are listed in Table 7 in order of the
percentage of total spectra detected. Sequences were compared to those present in the
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Candida Genome Database (CGD) and Saccharomyces Genome Database (SGD) to
determine sequence identity, as well as provide insight into the role of the potentially cointeracting proteins of C. albicans Cbr1.
The Cbr1 “bait” protein was abundantly found, thereby ensuring the specificity of
the potential interactions. Interestingly, nine ribosomal proteins were also detected, and
although they may not be actual protein interactions with the predominantly ER-specific
C. albicans protein, it does support the specificity of the subcellular compartment to
which the assay was confined [84].

Table 7. Proteins Indentified in Mass Spectrophotometric Analysis

Yeast alcohol dehydrogenase I and II proteins (ADH1 and ADH2) were also
detected in the mass spectrophotometric analysis. Adh1 functions in the conversion of
acetaldehyde to ethanol, whereas the fungal-specific Adh2 catalyzes the reaction in
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reverse when expressed in low sugar concentrations. Adh2 functions in the regeneration
of NADH, whereas Adh1 utilitizes NADH, with both reactions occurring in the
cytoplasm of the yeast cell. Since Cbr1 is a transmembrane protein that faces the cytosol,
these proteins may display interactions required for the constant cycle of NADH to
NAD+ conversion. Another alcohol dehydrogenase protein, Ife2, which plays a role in
morphogenesis and chlamydospore formation, was also detected [85].
The fungal-specific Pil1 (sphingolipid long chain base-responsive protein LSP1)
was also observed, and this protein is biofilm-induced and potentially involved in the
eiososome upon endocytosis [82, 86]. D-xylose reductase (Gre3) is also a potential
interacting protein of Cbr1 that is induced under weak acid stress, as well as associated
with the ergosterol biosynthesis genes, Erg2 (C-8 sterol isomerase) and Erg5 (C-22 sterol
desaturase) in S. cerevisiae Cbr1 [16, 78]. It is interesting to note that these potential cointeractors of C. albicans Cbr1 are soluble proteins and/or expressed only in the hyphal
stage of cell growth that is associated with C. albicans pathogenicity.
Elongation factor 1-alpha (Tef2/Tef1) is a possibly essential gene in yeast that
was observed as a potential interacting protein with C. albicans Cbr1 [82]. This protein
is macrophage- and pseudohyphal-induced, as well as upregulated in the RHE
(reconstituted human epithelium) model of oral candidiasis.
Although glycolysis proteins are abundant and often appear in mass
spectrophotometric analysis [84], it is worth to mention that glyceraldehyde-3-phosphate
(Tdh3;GAPDH;Gap1) and phosphoglycerate mutase 1 (Gpm1; PGAM) were observed.
Tdh3 is a soluble protein in hyphae that is also biofilm-, fluconazole-, and starvation-
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induced. Due to the role of cb5r in the ergosterol biosynthesis pathway, there may be a
correlation between these glycolytic enzymes and cb5r upon azole induction.
It was originally hypothesized that the dominant band at approximately 12 kDa
was the electron acceptor, cb5, of C. albicans Cbr1. However, this protein did not appear
anyway in the mass spectrophotometric analysis. Upon further thought, the Cbr1 protein
is in the oxidized phase during the protein pull-down assays, and therefore would not yet
have its subsequent interaction to reduce cb5.
The SGD reports 67 possible protein interactors of S. cerevisiae Cbr1, including
34 physical interactions and 20 genetic interactions. Ste20 and Ncp1, which were
discussed in the previous chapter, are included in the SGD database as physical and
genetic interactors, respectively. These interactions were determined by using a splitubiquitin system, and then confirmed using both Ste20 and Ncp1 as bait proteins in pulldown assays [82]. In our experiment using Cbr1 as the bait protein, we did not find
these, nor other CYP proteins; this may be due to differences between the yeast species as
well as experimental design and analysis. The only common protein found in our assay
and the SGD database was Hta2, a core histone protein required for chromatin assembly
and chromosome function, although the mechanism explaining this protein:protein
interaction is unknown.
It is important to understand the protein-protein interactions when in the
preliminary steps of drug discovery and development. Any proteins interacting with C.
albicans Cbr1 and related proteins are likely to affect drug interactions, and therefore
these interactions must be elucidated before moving forward into drug design. Also by
understanding the interactions that occur within the subcellular compartment of the cell to
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which the isoforms localize, we can better understand the response of cb5r to a variety of
signals within the cell. Protein interactions and networks that occur within the cell are a
complicated and complex web, and although all of the roles of cb5r have not been
elucidated, these results help us better understand the large network of interrelated
proteins and functions [44].
Some reports estimate that over 80% of proteins function in complexes, rather
than independently [87]. Although extensive genome sequence analysis has been done,
there is still the challenge of understanding the structure:function relationship that is
derived from this primary sequence of the gene of interest [88].

However, the

structure:function relationship only may not explain all of the network interactions that
occur within the physiological conditions of the cell [84, 89]. Many experiments create
conditions that mimic the cellular environment, such as in the reduced conditions created
by DTT in the previous experiments that emulate the cytoplasmic nature, the purpose of
which to detect weaker and/or transient interactions that occur with low affinity only
within specific environmental conditions. However, some of these interactions are still
too difficult to detect, especially if the experiment uses extensive washing procedures to
wash away contaminating and nonspecific proteins. Crosslinkers, such as DMS used in
this experiment, have provided a valuable tool to the field of protein interactions, in
assisting to detect weaker protein:protein interactions [90]. In our experiments, the use of
DMS helped to detect potential protein interactions of C. albicans Cbr1, including better
affinity of the smaller proteins.
This investigation into potential protein-protein interactions of C. albicans Cbr1
yielded some interesting potential novel interactions, although more specific analysis
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would have to be performed to confirm these interactions. Another future direction may
be to examine the protein-protein interactions of C. albicans cb5, the physiologic electron
acceptor of cb5r. Since cb5 did not appear on the mass spectrometric analysis, it would
imply that its oxidoreductase donor, cb5r, had not yet been reduced either. By using cb5
in experiments, it may utilize a downstream approach to further elucidating the role of
cb5r in its most functional conformation. It has also been speculated that the addition of
NADH in concentrations significantly higher than encountered in the subcellular
compartment may help in the reduction of cb5r to its functional form in this in vitro assay.
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CONCLUSIONS

Candida albicans is a common pathogen responsible for opportunistic fungal
infections that are a significant cause of morbidity and mortality among
immunocompromised persons. Although C. albicans exists as a commensal organism in
the majority of the population, it also has potential as a pathogen to cause serious disease
manifestations. The immune state of the host plays a role in the infectivity of C.
albicans, but the fungus also has its own set of virulence mechanisms necessary for
infection and survival. Such is the case of developing antifungal resistance to current
therapeutic options. There are already limited treatment options for fungal infections,
and this is further complicated by a continuously-changing resistance mechanisms.
Cytochrome b5 reductase serves as an example of a novel fungal therapeutic
target, due to its important and broad roles in metabolic processes such as fatty acid
desaturation, ergosterol biosynthesis, and cytochrome P450-mediated detoxification of
xenobiotics. Although extensive work has been performed on mammalian models of
cb5r, there has never been an investigative report of this protein in a pathogenic fungus
such as C. albicans. It was the intention of this research project to characterize the
kinetic, biochemical, and pharmacological properties of C. albicans cb5r, as compared to
the rat cb5r as the mammalian corresponding enzyme. The above findings describe the
initial-rate enzyme kinetics of both isoforms of C. albicans, Cbr1 and Mcr1, and have
been found to have similar substrate binding affinities and catalytic efficiencies, but a
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significantly decreased catalytic rate as compared to the mammalian counterpart. In
thermodynamic analysis studies, the fungal Cbr1 protein exhibited a decreased stability
as compared to mammalian thermal stability, and this was further supported by
differences in the in silico structural analysis. Inhibition studies were also performed to
investigate the pharmacological properties of fungal cb5r in the presence of selected
substrate analogues, nucleotide analogues, and other chemical compounds, and these
results indicate a difference in substrate specificity and conformational binding, as also
evident through ligand substrate binding analysis (LIGPLOT).

Upon the results of

enzyme inhibitors, a collaboration to discover more specific inhibitors of C. albicans
Cbr1 was developed. The fragment-based drug design approach yielded many potential
inhibitors, although more experimentation would be necessary as the inhibitors created
were not as successful as expected.
In the approach of novel fungal drug targets, the ergosterol biosynthetic pathway
has been a key area of focus. The allylamines specifically target Erg1, and the azole
family specifically targets Erg11. Although enzymes in the ergosterol pathway are prime
targets for antifungal drugs, there has been a recent emergence of experimental data that
supports that enzymes in this family may also be involved in resistance to the antifungal
drug. Erg3 and Erg5 have been identified in the azole resistance mechanism and AmB
resistance, and the above results describe the S. cerevisiae cb5r proteins that also appear
to also play a role in the AmB and azole resistance pathways. Understanding the proteins
involved in antifungal resistance is crucial in the creation of new targets, as well as nextgeneration antifungal agents with structural modifications necessary to bypass resistance.
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As new data describe the potential role of cb5r in resistance, as well as previously
documented reports of the involvement of Erg3 and Erg5, a logical next step in
understanding these mechanisms is the investigation of protein-protein interactions.
Using recombinant C. albicans Cbr1 protein in an affinity-based protein pull-down assay
and subsequent mass spectrometric analysis, several proteins were identified as potential
co-interactors of Cbr1. Interestingly, some of the proteins that were found in the analysis
also had implications in stress responses also including cb5r, such as members of the
alcohol dehydrogenase family, as well as Gre3 and Pil1 in conditions of weak acid stress.
Although not present in our pull-down assays, the recent report of overlapping functions
of Ncp1 and Cbr1 provides valuable insight into the role of the protein in electron
transfer with several CYP proteins. Further investigation into these potential interactions
is necessary, and new proteomic technologies may allow for identification of weak and/or
transient interactions that occur only within the physiological conditions of the cell.
In conclusion, C. albicans cb5r has appeal a potential novel fungal drug target,
due to differences in thermal and structural stability and substrate-binding specificity of
potential enzymatic inhibitors. However, experiments performed in gene knockout
studies involving S. cerevisiae implicate the role of both Cbr1 and Mcr1 isoforms in
azole and AmB resistance. The specific roles of cb5r and its electron acceptor, cb5, with
the CYP family are not fully understood, although it can be argued that it has a
significant role in ergosterol biosynthesis, AmB resistance and azole resistance in S.
cerevisiae, as well as the possibility of further functions not yet discovered.
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